

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	CAPplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/CAPplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	32	JAN 28	MARPAT searching enhanced
NEWS	33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment

NEWS 35 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
NEWS 36 FEB 08 STN Express, Version 8.3, now available

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 24 JANUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:12:41 ON 14 FEB 2008

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:12:55 ON 14 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 FEB 2008 HIGHEST RN 1003293-96-6
DICTIONARY FILE UPDATES: 13 FEB 2008 HIGHEST RN 1003293-96-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10577841.str



```

chain nodes :
14 15 16 17 18 19 20 21 26 27
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-14 2-18 3-19 5-21 6-20 7-17 15-16 15-17 15-21 15-26 26-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-12 7-8 8-9 9-10 10-11 11-12
exact/norm bonds :
1-2 1-6 1-14 2-3 2-18 3-4 3-19 4-5 5-6 5-21 6-20 7-17 15-16 15-17
15-21 15-26 26-27
normalized bonds :
7-12 7-8 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

```

```

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 26:CLASS 27:CLASS

```

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 12:13:30 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 2 TO 124

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 12:13:33 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 21 TO ITERATE

100.0% PROCESSED 21 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=> fil stnguide

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'STNGUIDE' ENTERED AT 12:13:41 ON 14 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Feb 8, 2008 (20080208/UP).

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.06

178.63

FILE 'REGISTRY' ENTERED AT 12:14:21 ON 14 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 FEB 2008 HIGHEST RN 1003293-96-6

DICTIONARY FILE UPDATES: 13 FEB 2008 HIGHEST RN 1003293-96-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of

experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10577841.str



chain nodes :

14 15 16 17 18 19 20 21 26 27

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12

chain bonds :

1-14 2-18 3-19 5-21 6-20 7-17 15-16 15-17 15-21 15-26 26-27

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-12 7-8 8-9 9-10 10-11 11-12

exact/norm bonds :

1-2 1-6 1-14 2-3 2-18 3-4 3-19 4-5 5-6 5-21 6-20 7-17 15-16 15-17
15-21 15-26 26-27

normalized bonds :

7-12 7-8 8-9 9-10 10-11 11-12

isolated ring systems :

containing 1 : 7 :

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 26:CLASS 27:CLASS

L4 STRUCTURE UPLOADED

=> d

L4 HAS NO ANSWERS

L4 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 14

SAMPLE SEARCH INITIATED 12:14:42 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 9 TO ITERATE

100.0% PROCESSED 9 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
PROJECTED ITERATIONS: 9 TO 360
PROJECTED ANSWERS: 7 TO 298

L5 7 SEA SSS SAM L4

=> s 14 full
FULL SEARCH INITIATED 12:14:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 253 TO ITERATE

100.0% PROCESSED 253 ITERATIONS 159 ANSWERS
SEARCH TIME: 00.00.01

L6 159 SEA SSS FUL L4

=> s 16 and caplus/lc
 56059609 CAPLUS/LC
L7 119 L6 AND CAPLUS/LC


=> s 16 not 17
L8 40 L6 NOT L7

=> s 18 35-40
MISSING OPERATOR

=> d 18 35-40

L8 ANSWER 35 OF 40 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 758684-59-2 REGISTRY
 ED Entered STN: 08 Oct 2004
 CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -phenyl-,
 (6R,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C20 H25 N O3
 CI CCM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 ANSWER 36 OF 40 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 757940-98-0 REGISTRY
 ED Entered STN: 07 Oct 2004
 CN 2-Morpholinemethanol, α -[(2-methylphenyl)methyl]- α -phenyl-,
 (6R,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 H23 N O2
 CI CCM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 ANSWER 37 OF 40 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 750570-01-5 REGISTRY
 ED Entered STN: 24 Sep 2004
 CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -phenyl-,
 (6R,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 H23 N O3
 CI CCM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 ANSWER 38 OF 40 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 744196-20-1 REGISTRY
 ED Entered STN: 14 Sep 2004
 CN 2-Morpholinemethanol, α -[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]-
 α -phenyl-, (6R,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H24 F N O2
 CI CCM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 ANSWER 39 OF 40 REGISTRY COPYRIGHT 2008 ACS on STN
RN 732983-60-7 REGISTRY
ED Entered STN: 26 Aug 2004
CN 2-Morpholinemethanol, α -([2-(1-methylethoxy)phenyl]methyl)- α -phenyl-, (4R,2S)- (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H27 N O3
CI CCM
SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 ANSWER 40 OF 40 REGISTRY COPYRIGHT 2008 ACS on STN
RN 701907-86-0 REGISTRY
ED Entered STN: 30 Jun 2004
CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -phenyl-, (4R,2S)- (CA INDEX NAME)
FS STEREOSEARCH
MF C24 H25 N O2
CI CCM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> fil caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	195.97	374.60

FILE 'CAPLUS' ENTERED AT 12:15:15 ON 14 FEB 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Feb 2008 VOL 148 ISS 7
 FILE LAST UPDATED: 13 Feb 2008 (20080213/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 12:12:41 ON 14 FEB 2008)

FILE 'REGISTRY' ENTERED AT 12:12:55 ON 14 FEB 2008

L1	STRUCTURE UPLOADED
L2	0 S L1
L3	0 S L1 FULL

FILE 'STNGUIDE' ENTERED AT 12:13:41 ON 14 FEB 2008

FILE 'REGISTRY' ENTERED AT 12:14:21 ON 14 FEB 2008

L4	STRUCTURE UPLOADED
L5	7 S L4
L6	159 S L4 FULL
L7	119 S L6 AND CAPLUS/LC
L8	40 S L6 NOT L7

FILE 'CAPLUS' ENTERED AT 12:15:15 ON 14 FEB 2008

=> s 17

L9	10 L7
----	-------

=> d ibib abs hitstr 1-10

L9 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:95116 CAPLUS
TITLE: Biomarker-optimized attention deficit-hyperactivity disorder (ADHD) treatment with selective norepinephrine reuptake inhibitors
INVENTOR(S): Lawrence, Donald Gilbert
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 8pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2008020387	A1	20080124	US 2007-694099	20070330
PRIORITY APPLN. INFO.:			US 2006-788008P	P 20060331

AB The invention provides methods for predicting patient responsiveness to treatment of attention-deficit/hyperactivity disorder (ADHD) with selective norepinephrine reuptake inhibitors; identifying individuals requiring a higher than normal dose of atomoxetine for treating ADHD; and predicting patient responsiveness to treatment of neuropsychiatric diseases or disorders responsive to treatment with selective norepinephrine reuptake inhibitors are provided. These methods are based on the identification of the variable number of tandem repeats (VNTR) polymorphism present in the 3'-untranslated region of the human dopamine transporter 1 (DAT 1) gene present in patient body fluid or tissue samples. Patients with a 10/10 VNTR genotype are considered poor responders to treatment with atomoxetine and other selective norepinephrine reuptake inhibitors for the indicated conditions.

IT 852236-82-9 852237-54-8 852237-54-8D, salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biomarker-optimized attention deficit-hyperactivity disorder and neuropsychiatric disorder treatment with selective norepinephrine reuptake inhibitors)
RN 852236-82-9 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1), (α R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.


L9 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl


RN 852237-54-8 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(tetrahydro-2H-pyran-4-yl)-, (α R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 852237-54-8 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(tetrahydro-2H-pyran-4-yl)-, (α R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.




L9 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L9 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1331209 CAPLUS
DOCUMENT NUMBER: 146:223523
TITLE: Synthesis of 11 C-labelled (R)-OHDMI and CFMME and their evaluation as candidate radioligands for
imaging central norepinephrine transporters with PET
AUTHOR(S): Schou, Magnus; Pike, Victor W.; Sovago, Judit; Gulyas, Balazs; Gallagher, Peter T.; Dobson, David R.; Walter, Magnus W.; Rudyk, Helene; Farde, Lars; Halldin, Christer
CORPORATE SOURCE: Karolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Karolinska Hospital,
SOURCE: Stockholm, S-17176, Swed.
Bioorganic & Medicinal Chemistry (2007), 15(2), 616-625
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:223523

AB (R)-1-(10,11-Dihydro-dibenzo[b,f]azepin-5-yl)-3-methylamino-propan-2-ol ((R)-OHDMI) and (S,S)-1-cyclopentyl-2-(5-fluoro-2-methoxy-phenyl)-1-morpholin-2-yl-ethanol (CFMME) were synthesized and found to be potent inhibitors of norepinephrine reuptake. Each was labeled efficiently in its Me group with carbon-11 ($t_{1/2}$ = 20.4 min) as a prospective radioligand for imaging brain norepinephrine transporters (NET) with positron emission tomog. (PET). The uptake and distribution of radioactivity in brain following i.v. injection of each radioligand into cynomolgus monkey was examined in vivo with PET. After injection of (R)-[11 C]OHDMI, the maximal whole brain uptake of radioactivity was very low (1.1% of injected dose; I.D.). For occipital cortex, thalamus, lower brainstem, mesencephalon and cerebellum, radioactivity ratios to striatum at 93 min after radioligand injection were 1.35, 1.35, 1.2, 1.2 and 1.0, resp. After injection of [11 C]CFMME, radioactivity readily entered brain (3.5% I.D.). Ratios of radioactivity to cerebellum at 93 min for thalamus, occipital cortex, region of locus coeruleus, mesencephalon and striatum were 1.35, 1.3, 1.2 and 1.2, resp. Radioactive metabolites in plasma were measured by radio-HPLC. (R)-[11 C]OHDMI represented 75% of plasma radioactivity at 4 min after injection and 6% at 30 min. After injection of [11 C]CFMME, 84% of the radioactivity in plasma represented parent at 4 min and 20% at 30 min. Since the two new hydroxylated radioligands provide only modest regional differentiation in brain uptake and form potentially troublesome lipophilic radioactive metabolites, they are concluded to be inferior to existing radioligands, such as (S,S)-[11 C]MeNER, (S,S)-[18 F]FMENER-D2 and (S,S)-[18 F]FRB-D4, for the study of brain NETs with PET in vivo.
IT 925232-43-5P
RL: DGN (Diagnostic use); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 11 C-labeled (R)-OHDMI and CFMME as candidate radioligands for PET imaging of central norepinephrine transporters)


L9 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 925232-43-5 CAPLUS
CN 2-Morpholinemethanol, α -cyclopentyl- α -[5-fluoro-2-(methoxy-11C)-phenyl]methyl]-, (α S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 925232-42-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 11C-labeled (R)-OHMI and CFMME as candidate radioligands for PET imaging of central norepinephrine transporters)
RN 925232-42-4 CAPLUS
CN 2-Morpholinemethanol, α -cyclopentyl- α -[5-fluoro-2-hydroxyphenyl]methyl]-, (α S,2S)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L9 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:588645 CAPLUS
DOCUMENT NUMBER: 143:115550
TITLE: Preparation of heterocyclic compounds as selective norepinephrine reuptake inhibitors for treating hot flashes, impulse control disorders and personality change due to a general medical condition
INVENTOR(S): Allen, Albert John; Hemrick-Luecke, Susan; Summer, Calvin Russell; Wallace, Owen Brendan
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 337 pp.
CODEN: PIXKD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060949	A2	20050707	WO 2004-US38221	20041201
WO 2005060949	A3	20050909		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2548304	A1	20050707	CA 2004-2548304	20041201
EP 1729754	A2	20061213	EP 2004-811076	20041201
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 1889940	A	20070103	CN 2004-80036841	20041201
JP 2007513945	T	20070531	JP 2006-543830	20041201
US 2007015786	A1	20070118	US 2006-581015	20060530
PRIORITY APPLN. INFO.:			US 2003-529428P	P 20031212
			WO 2004-US38221	W 20041201


OTHER SOURCE(S): MARPAT 143:115550
GI



AB The invention relates to a method of preventing or treating hot flashes,

L9 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
to vasomotor symptoms, impulse control disorders or personality change due to a general medical condition, comprising administering to a patient in need thereof a therapeutically effective amt. of a selective norepinephrine reuptake inhibitor selected from atomoxetine, reboxetine, I [X = alkylthio; Y = alkyl], II [n = 1-3; R1 = alkyl, alkenyl, cycloalkyl, etc.; R2-R4 = H, alkyl, alkoxy, etc.; R5-R6 = H, alkyl, alkoxy, halo; R7-R8 = H, alkyl; R9-R10 = H, halo, OH, CN, alkyl, alkoxy], etc. Over 200 title compts. such as I, II and other heterocyclic compts. disclosed, were prepd. E.g., a 2-step synthesis of N-(2-methylpropyl)-N-[(2-fluorophenyl)methyl]piperidin-4-amine fumarate, starting from tert-Bu 4-(2-methylpropylamino)piperidine-1-carboxylate and 2-fluorobenzaldehyde, was given. The preferred exemplified title compts. exhibit a Ki value less than 1 μ M, more preferably less than 500 nM at the norepinephrine transporter as detd. using the scintillation proximity assay.
IT 857642-46-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclic compts. as selective norepinephrine reuptake inhibitors for treating hot flashes, impulse control disorders and personality change due to general medical condition)
RN 857642-46-7 CAPLUS
CN 2-Morpholinemethanol, α -[5-fluoro-2-methoxyphenyl]methyl]- α -phenyl-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

IT 664360-82-1P 664361-41-5P 852236-27-2P
852236-29-4P 852236-33-0P 852236-35-2P 852236-37-4P 852236-38-5P
852236-39-6P 852236-40-9P 852236-42-1P
852236-43-2P 852236-44-3P 852236-45-4P
852236-47-6P 852236-49-8P 852236-51-2P
852236-53-4P 852236-55-6P 852236-56-7P
852236-58-9P 852236-60-3P 852236-63-6P
852236-65-8P 852236-66-9P 852236-68-1P
852236-70-5P 852236-72-7P 852236-74-9P
852236-76-1P 852236-78-3P 852236-84-1P
852431-21-1P 854139-91-6P 857642-38-7P


L9 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
857642-40-1P 857642-41-2P 857642-42-3P
857642-43-4P 857642-44-5P 857642-52-5P
857642-59-2P 857642-60-5P 857642-61-6P
857642-62-7P 857642-63-8P 857642-64-9P
857642-65-0P 857642-66-1P 857642-67-2P
857642-68-3P 857642-69-4P 857642-70-7P
857642-71-8P 857642-74-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclic compts. as selective norepinephrine reuptake inhibitors for treating hot flashes, impulse control disorders and personality change due to general medical condition)
RN 664360-82-1 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethyl)phenyl]methyl]-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-41-5 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethyl)phenyl]methyl]-, (α R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 852236-27-2 CAPLUS
CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-29-4 CAPLUS
CN 2-Morpholinemethanol, α -ethyl- α -[(5-fluoro-2-methoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-31-8 CAPLUS
CN 2-Morpholinemethanol, α -ethyl- α -[[2-(trifluoromethoxy)phenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-33-0 CAPLUS
CN 2-Morpholinemethanol, α -[(1,1'-biphenyl)-2-ylmethyl]- α -ethyl-, hydrochloride (9CI) (CA INDEX NAME)



RN 852236-39-6 CAPLUS
CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -(1-methylethyl)-, hydrochloride, (α R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 852236-40-9 CAPLUS
CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -(1-methylethyl)-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 852236-42-1 CAPLUS
CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -(1-methylethyl)-, (α R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl


RN 852236-35-2 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(1-methylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-37-4 CAPLUS
CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -(1-methylethyl)-, (α R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 852236-39-5 CAPLUS
CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -(1-methylethyl)-, (α R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 852236-43-2 CAPLUS
CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -(1-methylethyl)-, (α R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 852236-44-3 CAPLUS
CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -(1-methylethyl)-, hydrochloride, (α R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 852236-45-4 CAPLUS
CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -(1-methylethyl)-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 852236-47-6 CAPLUS
 CN 2-Morpholinemethanol, α-(1-methylethyl)-α-[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-49-8 CAPLUS
 CN 2-Morpholinemethanol, α-[(1,1'-biphenyl)-2-ylmethyl]-α-(1-methylethyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-51-2 CAPLUS
 CN 2-Morpholinemethanol, α-[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]-α-(1-methylethyl)-, hydrochloride (9CI) (CA INDEX NAME)




RN 852236-58-9 CAPLUS
 CN 2-Morpholinemethanol, α-(2-methylpropyl)-α-[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 852236-60-3 CAPLUS
 CN 2-Morpholinemethanol, α-[(1,1'-biphenyl)-2-ylmethyl]-α-(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)



RN 852236-63-6 CAPLUS
 CN 2-Morpholinemethanol, α-[(1,1'-biphenyl)-2-ylmethyl]-α-(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl



● HCl


RN 852236-53-4 CAPLUS
 CN 2-Morpholinemethanol, α-[(5-fluoro-2-methoxyphenyl)methyl]-α-(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 852236-55-6 CAPLUS
 CN 2-Morpholinemethanol, α-[(2-ethoxyphenyl)methyl]-α-(2-methylpropyl)-, (αR,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 852236-56-7 CAPLUS
 CN 2-Morpholinemethanol, α-[(2-ethoxyphenyl)methyl]-α-(2-methylpropyl)-, (αR,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.

RN 852236-65-8 CAPLUS
 CN 2-Morpholinemethanol, α-[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]-α-(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-66-9 CAPLUS
 CN 2-Morpholinemethanol, α-[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]-α-(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)




RN 852236-68-1 CAPLUS
 CN 2-Morpholinemethanol, α-cyclopentyl-α-[(5-fluoro-2-methoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-70-5 CAPLUS
 CN 2-Morpholinemethanol, α-cyclopentyl-α-[(2-ethoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-72-7 CAPLUS
CN 2-Morpholinemethanol, α -cyclopentyl- α -[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-74-9 CAPLUS
CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -cyclopentyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-76-1 CAPLUS

RN 852431-21-1 CAPLUS
CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -cyclopentyl-, hydrochloride (9CI) (CA INDEX NAME)



RN 854139-91-6 CAPLUS
CN 2-Morpholinemethanol, α -[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 857642-38-7 CAPLUS
CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 857642-40-1 CAPLUS
CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)

CN 2-Morpholinemethanol, α -cyclopentyl- α -[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-78-3 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(tetrahydro-2H-pyran-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-84-1 CAPLUS
CN 2-Morpholinemethanol, α -(tetrahydro-2H-pyran-4-yl)- α -[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 857642-41-2 CAPLUS
CN 2-Morpholinemethanol, α -[[2-(1-methylethoxy)phenyl]methyl]- α -phenyl-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 857642-42-3 CAPLUS
CN 2-Morpholinemethanol, α -(3-fluorophenyl)- α -[(2-methoxyphenyl)methyl]-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 857642-43-4 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethoxy)phenyl)methyl]-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




● HCl

RN 857642-44-5 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -phenyl-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl




● HCl

RN 857642-61-6 CAPLUS
 CN 2-Morpholinemethanol, α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)




RN 857642-62-7 CAPLUS
 CN 2-Morpholinemethanol, α -[(4'-methyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)



RN 857642-63-8 CAPLUS
 CN 2-Morpholinemethanol, α -[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)

RN 857642-52-5 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-methylphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 857642-59-2 CAPLUS
 CN 2-Morpholinemethanol, α -[(2'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl


RN 857642-60-5 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-hydroxyphenyl)methyl]- α -phenyl-, hydrochloride (9CI) (CA INDEX NAME)




RN 857642-64-9 CAPLUS
 CN 2-Morpholinemethanol, α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)




RN 857642-65-0 CAPLUS
 CN 2-Morpholinemethanol, α -[(3'-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)




RN 857642-66-1 CAPLUS
 CN 2-Morpholinemethanol, α -[(3'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)





RN 857642-67-2 CAPLUS
CN 2-Morpholinemethanol, α-[(3'-methoxy[1,1'-biphenyl]-2-yl)methyl]-α-phenyl- (CA INDEX NAME)




RN 857642-68-3 CAPLUS
CN 2-Morpholinemethanol, α-[(3'-methyl[1,1'-biphenyl]-2-yl)methyl]-α-phenyl- (CA INDEX NAME)




RN 857642-69-4 CAPLUS
CN 2-Morpholinemethanol, α-[(3',5'-dichloro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl- (CA INDEX NAME)



RN 857642-70-7 CAPLUS
CN 2-Morpholinemethanol, α-[(2',4'-dimethyl[1,1'-biphenyl]-2-yl)methyl]-α-phenyl- (CA INDEX NAME)



RN 857642-71-8 CAPLUS
CN 2-Morpholinemethanol, α-[(2',4'-dimethoxy[1,1'-biphenyl]-2-yl)methyl]-α-phenyl- (CA INDEX NAME)





RN 857642-74-1 CAPLUS
CN 2-Morpholinemethanol, α-[(3',4'-dichloro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl- (CA INDEX NAME)

ACCESSION NUMBER: 2005:523264 CAPLUS
DOCUMENT NUMBER: 143:59831
TITLE: A preparation of aminopiperidine derivatives, useful for the treatment of cognitive failure
INVENTOR(S): Hatfield, Alan Kramer; Bymaster, Franklin Porter; McKinzie, David Lee; Tucker, Tina Marie; Keaffaber, Kirk Matthew; Sumner, Calvin Russell; Trzepacz, Paula Terese; Allen, Albert John; Kelsey, Douglas Kenneth; Michelson, David; Gehlert, Donald Richard; Yang, Charles Renkin
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 300 pp.
CODEN: FIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053663	A2	20050616	WO 2004-US37195	20041124
WO 2005053663	A3	20050811		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:		US 2003-524450P	P	20031124
		US 2003-524781P	P	20031125

OTHER SOURCE(S): MARPAT 143:59831
GI



AB The invention relates to a preparation of aminopiperidine derivs. of formula I
[wherein: x is 1-3; R¹ is (un)substituted phenyl; R² and R⁵ are independently H or alkyl; R³ is (cyclo)alkyl, alkenyl, or cycloalkylalkyl,

L9 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 etc.; R4 is H, halogen, or OH, etc.; R6 is H, halogen, CN, or alkyl,
 etc.], useful for the treatment of cognitive failure. Selective
 norepinephrine reuptake inhibitors were used to treat cognitive failure.
 For instance, fumarate salt of aminopiperidine deriv. II was prepd. via
 imination of 2-fluorobenzaldehyde by tert-Bu 4-[(2-
 methylpropyl)amino]piperidine-1-carboxylate, redn. of the obtained imine,
 and subsequent fumaric acid salt formation. The preferred invention
 compds. exhibit Ki values less than 500 nM at the norepinephrine
 transporter.


IT 664360-72-9P 664360-73-0P 664360-74-1P
 664360-75-2P 664360-76-3P 664360-77-4P
 664360-79-6P 664360-82-1P 664360-84-3P
 664360-88-7P 664360-89-8P 854139-91-6P
 854139-92-7P 854139-93-8P 854139-94-9P
 854139-95-0P 854139-96-1P 854139-97-2P
 854139-98-3P 854139-99-4P 854140-00-4P
 854140-01-5P 854140-04-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of aminopiperidine derivs. useful for the treatment of
 cognitive failure)

RN 664360-72-9 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -phenyl-,
 hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 664360-73-0 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -phenyl-,
 hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 664360-76-3 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-(
 trifluoromethoxy)phenyl]methyl]-, hydrochloride, (α R,2S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-77-4 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -phenyl-,
 hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-79-6 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -
 phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 664360-74-1 CAPLUS
 CN 2-Morpholinemethanol, α -[[2-(1-methylethoxy)phenyl]methyl]- α -
 phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 664360-75-2 CAPLUS
 CN 2-Morpholinemethanol, α -(3-fluorophenyl)- α -[(2-
 methoxyphenyl)methyl]-, hydrochloride, (α R,2S)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



● HCl


L9 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl


RN 664360-82-1 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-(
 trifluoromethyl)phenyl]methyl]-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664360-84-3 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-methylphenyl)methyl]- α -phenyl-,
 hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-88-7 CAPLUS
 CN 2-Morpholinemethanol, α -[(2'-chloro[1,1'-biphenyl]-2-yl)methyl]-
 α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-89-8 CAPLUS
 CN 2-Morpholinemethanol, α-[(5-fluoro-2-hydroxyphenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 854139-91-6 CAPLUS
 CN 2-Morpholinemethanol, α-[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, hydrochloride, (αR,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl




RN 854139-95-0 CAPLUS
 CN 2-Morpholinemethanol, α-[(3'-fluoro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 854139-96-1 CAPLUS
 CN 2-Morpholinemethanol, α-[(3'-chloro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 854139-97-2 CAPLUS
 CN 2-Morpholinemethanol, α-[(3'-methoxy[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.


RN 854139-92-7 CAPLUS
 CN 2-Morpholinemethanol, α-[(4'-methyl[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 854139-93-8 CAPLUS
 CN 2-Morpholinemethanol, α-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 854139-94-9 CAPLUS
 CN 2-Morpholinemethanol, α-[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 854139-98-3 CAPLUS
 CN 2-Morpholinemethanol, α-[(3'-methyl[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 854139-99-4 CAPLUS
 CN 2-Morpholinemethanol, α-[(3',5'-dichloro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 854140-00-4 CAPLUS
 CN 2-Morpholinemethanol, α-[(2',4'-dimethyl[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.

L9 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 854140-01-5 CAPLUS
CN 2-Morpholinemethanol, α -[(2',4'-dimethoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 854140-04-8 CAPLUS
CN 2-Morpholinemethanol, α -[(3',4'-dichloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 664361-42-6P


L9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:451370 CAPLUS
DOCUMENT NUMBER: 142:482071
TITLE: Preparation of morpholine derivatives as norepinephrine reuptake inhibitors
INVENTOR(S): Campbell, Gordon Iain; Cases-Thomas, Manuel Javier; Man, Teresa; Masters, John Joseph; Rudyk, Helene Catherine Eugenie; Walter, Magnus Wilhelm
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005047272	A1	20050526	WO 2004-US32771	20041028
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004289616	A1	20050526	AU 2004-289616	20041028
CA 2544649	A1	20050526	CA 2004-2544649	20041028
EP 1682523	A1	20060726	EP 2004-794209	20041028
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
HR				
CN 1878762	A	20061213	CN 2004-80033115	20041028
BR 2004015273	A	20061219	BR 2004-15273	20041028
JP 2007510720	T	20070426	JP 2006-539492	20041028
US 2007083046	A1	20070412	US 2006-577841	20060429
MX 2006PA05226	A	20060720	MX 2006-PAS226	20060509
KR 783855	B1	20071210	KR 2006-708999	20060509
NO 2006002700	A	20060808	NO 2006-2700	20060612
PRIORITY APPLN. INFO.:			GB 2003-26148	A 20031110
			US 2004-535459P	P 20040109
			WO 2004-US32771	W 20041028



OTHER SOURCE(S): CASREACT 142:482071; MARPAT 142:482071
GI

L9 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of aminopiperidine derivs. useful for the treatment of cognitive failure)
RN 664361-42-6 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-hydroxyphenyl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB Title compds. I [X = OH, alkoxy, NH₂, etc.; R independently = H, alkyl, with provisions; R¹ = (un)substituted-alkyl, -alkoxy, CN, etc.; R² = H, alkyl; R³ = H, alkyl; Ar = (un)substituted-Ph, -5- to 6-membered heteroaryl] and their pharmaceutically acceptable salts, are prepared and disclosed as norepinephrine reuptake inhibitors. Thus, e.g., II was prepared by conversion of 4-benzyl-morpholine-2-carbonitrile into the resp. carboxylic Et ester followed by amidation with N,N-dimethylhydroxylamine and subsequent Grignard reactions with Me magnesium bromide and 2-phenylbenzyl magnesium bromide followed by debenzylation and conversion into the HCl salt. The activity of I was evaluated in a CYF2D6 inhibition assay and preferred compds. of the invention exhibited an IC₅₀ higher than 6 μ M. I as norepinephrine reuptake inhibitors should prove useful in the treatment of disorders that are associated with norepinephrine dysfunction. Pharmaceutical compns. comprising I are disclosed.
IT 852236-82-9P
RL: IMP (Industrial manufacture); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of morpholine derivs. as norepinephrine reuptake inhibitors)
RN 852236-82-9 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1), (α R,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.



● HCl



IT 852236-37-4P 852236-38-5P 852236-42-1P
 852236-43-2P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of morpholine derivs. as norepinephrine reuptake inhibitors)
 RN 852236-37-4 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -(1-methylethyl)-, (α R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 852236-38-5 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -(1-methylethyl)-, (α R,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.




RN 852237-02-6 CAPLUS
 CN 2-Morpholinemethanol, α -[(1,1'-biphenyl)-2-ylmethyl]- α -(4,4,4-trifluorobutyl)- (CA INDEX NAME)



RN 852237-05-9 CAPLUS
 CN 2-Morpholinemethanol, α -cyclopropyl- α -[(2-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 852237-08-2 CAPLUS
 CN 2-Morpholinemethanol, α -cyclopropyl- α -[(2-ethoxyphenyl)methyl]- (CA INDEX NAME)



RN 852237-11-7 CAPLUS
 CN 2-Morpholinemethanol, α -[(1,1'-biphenyl)-2-ylmethyl]- α -cyclopropyl- (CA INDEX NAME)


RN 852236-42-1 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -(1-methylethyl)-, (α R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 852236-43-2 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -(1-methylethyl)-, (α R,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.




IT 852236-60-3P 852236-87-4P 852237-02-6P
 852237-05-9P 852237-08-2P 852237-11-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of morpholine derivs. as norepinephrine reuptake inhibitors)
 RN 852236-60-3 CAPLUS
 CN 2-Morpholinemethanol, α -[(1,1'-biphenyl)-2-ylmethyl]- α -(2-methylpropyl)- (CA INDEX NAME)



RN 852236-87-4 CAPLUS
 CN 2-Morpholinemethanol, α -[(1,1'-biphenyl)-2-ylmethyl]- α -(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




IT 852236-27-2P 852236-29-4P 852236-31-8P
 852236-33-0P 852236-35-2P 852236-39-6P
 852236-40-9P 852236-44-3P 852236-45-4P
 852236-47-6P 852236-49-8P 852236-51-2P
 852236-53-4P 852236-55-6P 852236-56-7P
 852236-58-9P 852236-63-6P 852236-65-8P
 852236-68-1P 852236-70-5P 852236-72-7P
 852236-74-9P 852236-76-1P 852236-78-3P
 852236-84-1P 852236-86-3P 852236-90-9P
 852236-93-2P 852236-95-4P 852236-97-6P
 852236-99-8P 852237-01-5P 852237-04-8P
 852237-07-1P 852237-10-6P 852237-14-0P
 852237-21-9P 852237-23-1P 852237-53-7P
 852237-54-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of morpholine derivs. as norepinephrine reuptake inhibitors)
 RN 852236-27-2 CAPLUS
 CN 2-Morpholinemethanol, α -[(1,1'-biphenyl)-2-ylmethyl]- α -methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-29-4 CAPLUS
 CN 2-Morpholinemethanol, α -ethyl- α -[(5-fluoro-2-methoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-31-8 CAPLUS
CN 2-Morpholinemethanol, α -ethyl- α -[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 852236-33-0 CAPLUS
CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -ethyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-35-2 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(1-methylethyl)-, hydrochloride (9CI) (CA INDEX NAME)

L9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
methylethyl)-, hydrochloride, (α R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 852236-45-4 CAPLUS
CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -(1-methylethyl)-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 852236-47-6 CAPLUS
CN 2-Morpholinemethanol, α -(1-methylethyl)- α -[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl



● HCl

RN 852236-39-6 CAPLUS
CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -(1-methylethyl)-, hydrochloride, (α R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 852236-40-9 CAPLUS
CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -(1-methylethyl)-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 852236-44-3 CAPLUS
CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -(1-


L9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
methyl)-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 852236-51-2 CAPLUS
CN 2-Morpholinemethanol, α -[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -(1-methylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-53-4 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-55-6 CAPLUS
CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -(2-methylpropyl)-, (α R,2R)-rel- (CA INDEX NAME)

L9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Relative stereochemistry.




RN 852236-56-7 CAPLUS
CN 2-Morpholinemethanol, α-[(2-ethoxyphenyl)methyl]-α-(2-methylpropyl)-, (αR,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 852236-58-9 CAPLUS
CN 2-Morpholinemethanol, α-(2-methylpropyl)-α-[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-63-6 CAPLUS
CN 2-Morpholinemethanol, α-([1,1'-biphenyl]-2-ylmethyl)-α-(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)

L9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




● HCl

RN 852236-72-7 CAPLUS
CN 2-Morpholinemethanol, α-cyclopentyl-α-[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-74-9 CAPLUS
CN 2-Morpholinemethanol, α-([1,1'-biphenyl]-2-ylmethyl)-α-cyclopentyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-76-1 CAPLUS
CN 2-Morpholinemethanol, α-cyclopentyl-α-(4-fluoro[1,1'-

L9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




● HCl

RN 852236-65-8 CAPLUS
CN 2-Morpholinemethanol, α-[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]-α-(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-68-1 CAPLUS
CN 2-Morpholinemethanol, α-cyclopentyl-α-[(5-fluoro-2-methoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-70-5 CAPLUS
CN 2-Morpholinemethanol, α-cyclopentyl-α-[(2-ethoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)

L9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
biphenyl]-2-yl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-78-3 CAPLUS
CN 2-Morpholinemethanol, α-[(5-fluoro-2-methoxyphenyl)methyl]-α-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-84-1 CAPLUS
CN 2-Morpholinemethanol, α-(tetrahydro-2H-pyran-4-yl)-α-[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

L9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 852236-86-3 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -(tetrahydro-2H-pyran-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-90-9 CAPLUS
 CN 2-Morpholinemethanol, α -[(3'-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -(tetrahydro-2H-pyran-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-93-2 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(3,3,3-trifluoropropyl)-, hydrochloride (9CI) (CA INDEX NAME)

L9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




● HCl

RN 852237-01-5 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -(4,4,4-trifluorobutyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852237-04-8 CAPLUS
 CN 2-Morpholinemethanol, α -cyclopropyl- α -[(2-methoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852237-07-1 CAPLUS
 CN 2-Morpholinemethanol, α -cyclopropyl- α -[(2-ethoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)

L9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




● HCl

RN 852236-95-4 CAPLUS
 CN 2-Morpholinemethanol, α -[[2-(trifluoromethoxy)phenyl]methyl]- α -(3,3,3-trifluoropropyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-97-6 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -(3,3,3-trifluoropropyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-99-8 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(4,4,4-trifluorobutyl)-, hydrochloride (9CI) (CA INDEX NAME)

L9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




● HCl

RN 852237-10-6 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -cyclopropyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852237-14-0 CAPLUS
 CN 2-Morpholinemethanol, α , α -bis[(2-methoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852237-21-9 CAPLUS
 CN 2-Morpholinemethanol, α -butyl- α -[(2-methoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852237-23-1 CAPLUS
CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -butyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852237-53-7 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 852237-54-8 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(tetrahydro-2H-pyran-4-yl)-, (α R,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.



IT 852236-66-9P 852236-91-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of morpholine derivs. as norepinephrine reuptake inhibitors)
RN 852236-66-9 CAPLUS
CN 2-Morpholinemethanol, α -[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -(2-methylpropyl)- (CA INDEX NAME)



RN 852236-91-0 CAPLUS
CN 2-Morpholinemethanol, α -[(3'-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)





REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L9 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:216719 CAPLUS
DOCUMENT NUMBER: 142:291416
TITLE: Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
INVENTOR(S): Kelsey, Douglas Kenneth
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 299 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005021095	A2	20050310	WO 2004-US25591	20040825
WO 2005021095	A3	20050609		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2532349	A1	20050310	CA 2004-2532349	20040825
EP 1660185	A2	20060531	EP 2004-780429	20040825
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
US 2007032554	A1	20070208	US 2006-568269	20060214
PRIORITY APPLN. INFO.:			US 2003-498018P	P 20030827
			WO 2004-US25591	W 20040825

OTHER SOURCE(S): MARPAT 142:291416
GI




AB Provided are methods and medicaments for treating stuttering or another communication disorder, comprising administering to a patient in need of such treatment an effective amount of a selective norepinephrine reuptake inhibitor. The invention discloses the use of atomoxetine, racemic reboxetine, (S,S)-reboxetine, and compds. of formula I [wherein X = alkylthio and Y = alkyl; as described in U.S. patent Number 5,281,624],

as well as their pharmaceutically acceptable salts, as the norepinephrine reuptake inhibitors described for treatment purposes. The invention further discloses the preparation of addnl. heterocyclic derivs. (as well as their pharmaceutically acceptable salts) that possess ability to serve as norepinephrine reuptake inhibitors. For instance, morpholine derivative I•HCl was prepared via alkylation of (4-benzyl-morpholin-2-yl)(phenyl)methanone with 2-chloro-6-fluorobenzylmagnesium chloride and subsequent N-debenzylation. The preferred invention compds. exhibited KI values of less than 500 nM at the norepinephrine transporter (scintillation proximity assay).

IT 664360-72-9P 664360-73-0P 664360-74-1P
664360-75-2P 664360-76-3P 664360-77-4P
664360-79-6P 664360-82-1P 664360-84-3P
664360-88-7P 664360-89-8P 664360-96-7P
664360-97-8P 664360-98-9P 664360-99-0P
664361-00-6P 664361-01-7P 664361-02-8P
664361-03-9P 664361-04-0P 664361-05-1P
664361-06-2P 664361-09-5P 664361-42-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. useful as norepinephrine reuptake inhibitors)
RN 664360-72-9 CAPLUS

L9 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-73-0 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 664360-74-1 CAPLUS
 CN 2-Morpholinemethanol, α -[[2-(1-methylethoxy)phenyl]methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


L9 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 664360-79-6 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-82-1 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl-alpha-[[2-(trifluoromethyl)phenyl]methyl]-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664360-84-3 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-methylphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 664360-75-2 CAPLUS
 CN 2-Morpholinemethanol, α -(3-fluorophenyl)- α -[(2-methoxyphenyl)methyl]-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-76-3 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl-alpha-[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-77-4 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 664360-88-7 CAPLUS
 CN 2-Morpholinemethanol, α -[(2'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-89-8 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-hydroxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

L9 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 664360-96-7 CAPLUS
 CN 2-Morpholinemethanol, α -[(4'-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, ($\alpha R, 2S$)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



• HCl

RN 664360-97-8 CAPLUS
 CN 2-Morpholinemethanol, α -[(4'-methyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664360-98-9 CAPLUS
 CN 2-Morpholinemethanol, α -[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 664361-02-8 CAPLUS
 CN 2-Morpholinemethanol, α -[(3'-methoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664361-03-9 CAPLUS
 CN 2-Morpholinemethanol, α -[(3'-methyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)


Absolute stereochemistry.



RN 664361-04-0 CAPLUS
 CN 2-Morpholinemethanol, α -[(3',5'-dichloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 664360-99-0 CAPLUS
 CN 2-Morpholinemethanol, α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-00-6 CAPLUS
 CN 2-Morpholinemethanol, α -[(3'-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-01-7 CAPLUS
 CN 2-Morpholinemethanol, α -[(3'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)

L9 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 664361-05-1 CAPLUS
 CN 2-Morpholinemethanol, α -[(2',4'-dimethyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-06-2 CAPLUS
 CN 2-Morpholinemethanol, α -[(2',4'-dimethoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664361-09-5 CAPLUS
 CN 2-Morpholinemethanol, α -[(3',4'-dichloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)


Absolute stereochemistry.



RN 664361-42-6 CAPLUS

CN 2-Morpholinemethanol, α -[(5-fluoro-2-hydroxyphenyl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



ACCESSION NUMBER: 2005:216660 CAPLUS
 DOCUMENT NUMBER: 142:291415
 TITLE: Treatment of pervasive development disorders employing
 INVENTOR(S): norepinephrine reuptake inhibitors
 PATENT ASSIGNEE(S): Allen, Albert John; Kelsey, Douglas Kenneth
 SOURCE: Eli Lilly and Company, USA
 PCT Int. Appl., 300 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020976	A2	20050310	WO 2004-US25593	20040825
WO 2005020976	A3	20050616		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2536161	A1	20050310	CA 2004-2536161	20040825
EP 1660065	A2	20060531	EP 2004-780431	20040825
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 2006241188	A1	20061026	US 2006-568466	20060214
PRIORITY APPLN. INFO.:				
			US 2003-498146P	P 20030827
			WO 2004-US25593	W 20040825

OTHER SOURCE(S): CASREACT 142:291415; MARPAT 142:291415
 GI



AB Provided are methods and medicaments for treating a pervasive development disorder, comprising administering to a patient in need of such treatment

L9 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 an effective amt. of a selective norepinephrine reuptake inhibitor. The invention discloses the use of atomoxetine, racemic reboxetine, (S,S)-reboxetine, and compds. of formula I [wherein X = alkylthio and Y = alkyl; as described in U.S. patent No. 5,281,624], as well as their pharmaceutically acceptable salts, as the norepinephrine reuptake inhibitors described for treatment purposes. The invention further discloses the prepn. of addnl. heterocyclic derivs. (as well as their pharmaceutically acceptable salts) that possess ability to serve as norepinephrine reuptake inhibitors. For instance, morpholine deriv. II•HCl (R = H) was prepd. via alkylation of (4-benzyl-morpholin-2-yl)(phenyl)methanone by 2-chloro-6-fluorobenzylmagnesium chloride and subsequent N-debenzylation of the obtained alc. I (R = Bn). The preferred

invention compds. exhibited Ki values of less than 500 nM at the norepinephrine transporter (scintillation proximity assay).

IT 664360-72-9P 664360-73-OP 664360-74-1P
 664360-75-2P 664360-76-3P 664360-77-4P
 664360-79-6P 664360-82-1P 664360-84-3P
 664360-88-7P 664360-89-8P 664360-96-7P
 664360-97-8P 664360-98-9P 664360-99-0P
 664361-00-6P 664361-01-7P 664361-02-8P
 664361-03-9P 664361-04-OP 664361-05-1P
 664361-06-2P 664361-09-5P 664361-42-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. useful as norepinephrine reuptake inhibitors)

RN 664360-72-9 CAPLUS

CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-73-0 CAPLUS

CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-74-1 CAPLUS

CN 2-Morpholinemethanol, α -[[2-(1-methylethoxy)phenyl]methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-75-2 CAPLUS

CN 2-Morpholinemethanol, α -(3-fluorophenyl)- α -[(2-methoxyphenyl)methyl]-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-76-3 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-77-4 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-79-6 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 664360-82-1 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethyl)phenyl]methyl]-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664360-84-3 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-methylphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-88-7 CAPLUS
 CN 2-Morpholinemethanol, α -[(2'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-89-8 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-hydroxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-96-7 CAPLUS
 CN 2-Morpholinemethanol, α -[(4'-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 664360-97-8 CAPLUS
 CN 2-Morpholinemethanol, α -[(4'-methyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664360-98-9 CAPLUS
 CN 2-Morpholinemethanol, α -[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664360-99-0 CAPLUS
 CN 2-Morpholinemethanol, α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-00-6 CAPLUS
CN 2-Morpholinemethanol, α -[(3'-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-01-7 CAPLUS
CN 2-Morpholinemethanol, α -[(3'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-02-8 CAPLUS
CN 2-Morpholinemethanol, α -[(3'-methoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-06-2 CAPLUS
CN 2-Morpholinemethanol, α -[(2',4'-dimethoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-09-5 CAPLUS
CN 2-Morpholinemethanol, α -[(3',4'-dichloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-42-6 CAPLUS




RN 664361-03-9 CAPLUS
CN 2-Morpholinemethanol, α -[(3'-methyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664361-04-0 CAPLUS
CN 2-Morpholinemethanol, α -[(3',5'-dichloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-05-1 CAPLUS
CN 2-Morpholinemethanol, α -[(2',4'-dimethyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.

CN 2-Morpholinemethanol, α -[(5-fluoro-2-hydroxyphenyl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.





L9 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:216659 CAPLUS
 DOCUMENT NUMBER: 142:291414
 TITLE: Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
 INVENTOR(S): Sumner, Calvin Russell
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 304 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020975	A2	20050310	WO 2004-US25592	20040825
WO 2005020975	A3	20050602		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG CA 2530014 A1 20050310 CA 2004-2530014 20040825 EP 1660064 A2 20060531 EP 2004-780430 20040825 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK US 2007105960 A1 20070510 US 2006-568244 20060214 PRIORITY APPLN. INFO.: US 2003-498019P P 20030827 WO 2004-US25592 W 20040825				

OTHER SOURCE(S): MARPAT 142:291414
 GI


L9 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB Provided are methods and medicaments for treating a learning disability or
 a motor skills disorder, comprising administering to a patient in need of such treatment an effective amount of a selective norepinephrine reuptake inhibitor. The invention discloses the use of atomoxetine, racemic reboxetine, (S,S)-reboxetine, and compds. of formula I [wherein X = alkylthio and Y = alkyl; as described in U.S. patent Number 5,281,624],
 as well as their pharmaceutically acceptable salts, as the norepinephrine reuptake inhibitors described for treatment purposes. The invention further discloses the preparation of addnl. heterocyclic derivs. (as well as their pharmaceutically acceptable salts) that possess ability to serve as norepinephrine reuptake inhibitors. For instance, morpholine derivative II•HCl was prepared via alkylation of (4-benzyl-morpholin-2-yl)(phenyl)methanone with 2-chloro-6-fluorobenzylmagnesium chloride and subsequent N-debenzylation. The preferred invention compds. exhibited KI values of less than 500 nM at the norepinephrine transporter (scintillation proximity assay).
 IT 664360-72-9P 664360-73-OP 664360-74-1P
 664360-75-2P 664360-76-3P 664360-77-4P
 664360-79-6P 664360-82-1P 664360-84-3P
 664360-88-7P 664360-89-8P 664360-96-7P
 664360-97-8P 664360-98-9P 664360-99-OP
 664361-00-6P 664361-01-7P 664361-02-8P
 664361-03-9P 664361-04-OP 664361-05-1P
 664361-06-2P 664361-09-5P 664361-42-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterocyclic compds. useful as norepinephrine reuptake inhibitors)


L9 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 664360-72-9 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 664360-73-0 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 664360-74-1 CAPLUS
 CN 2-Morpholinemethanol, α -[[2-(1-methylethoxy)phenyl]methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L9 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 664360-75-2 CAPLUS
 CN 2-Morpholinemethanol, α -(3-fluorophenyl)- α -[(2-methoxyphenyl)methyl]-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 664360-76-3 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 664360-77-4 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-79-6 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -phenyl-, hydrochloride, ($\alpha R, 2S$)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 664360-82-1 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethyl)phenyl]methyl]-, ($\alpha R, 2S$)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664360-84-3 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-methylphenyl)methyl]- α -phenyl-, hydrochloride, ($\alpha R, 2S$)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-88-7 CAPLUS
 CN 2-Morpholinemethanol, α -[(2'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, ($\alpha R, 2S$)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-89-8 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-hydroxyphenyl)methyl]- α -phenyl-, hydrochloride, ($\alpha R, 2S$)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-96-7 CAPLUS
 CN 2-Morpholinemethanol, α -[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, ($\alpha R, 2S$)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 664360-97-8 CAPLUS
 CN 2-Morpholinemethanol, α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664360-98-9 CAPLUS
 CN 2-Morpholinemethanol, α -[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664360-99-0 CAPLUS
 CN 2-Morpholinemethanol, α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-00-6 CAPLUS
 CN 2-Morpholinemethanol, α -[(3'-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-01-7 CAPLUS
 CN 2-Morpholinemethanol, α -[(3'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-02-8 CAPLUS
 CN 2-Morpholinemethanol, α -[(3'-methoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664361-03-9 CAPLUS
 CN 2-Morpholinemethanol, α -[(3'-methyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 664361-04-0 CAPLUS
 CN 2-Morpholinemethanol, α -[(3',5'-dichloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)



Absolute stereochemistry.

Absolute stereochemistry.




RN 664361-42-6 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-hydroxyphenyl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-05-1 CAPLUS
 CN 2-Morpholinemethanol, α -[(2',4'-dimethyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664361-06-2 CAPLUS
 CN 2-Morpholinemethanol, α -[(2',4'-dimethoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664361-09-5 CAPLUS
 CN 2-Morpholinemethanol, α -[(3',4'-dichloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

ACCESSION NUMBER: 2004:1036891 CAPLUS
 DOCUMENT NUMBER: 142:16841
 TITLE: Treatment of emotional dysregulation
 INVENTOR(S): Allen, Albert John; Cloutier, Kathleen Ann; Michelson, David; Reinmehrr, Frederick William
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 155 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103356	A2	20041202	WO 2004-US13005	20040511
WO 2004103356	A3	20050331		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-470752P P 20030515


OTHER SOURCE(S): MARPAT 142:16841
 AB Provided is a method of treating emotional dysregulation comprising administering to a patient in need of such treatment a selective norepinephrine reuptake inhibitor.

IT 664360-72-9P 664360-73-OP 664360-74-1P
 664360-76-3P 664360-77-4P 664360-79-6P
 664360-82-1P 664360-84-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (treatment of emotional dysregulation)


RN 664360-72-9 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 664360-73-0 CAPLUS
CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-74-1 CAPLUS
CN 2-Morpholinemethanol, α -[[2-(1-methylethoxy)phenyl]methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-76-3 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 664360-84-3 CAPLUS
CN 2-Morpholinemethanol, α -[(2-methylphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl



● HCl

RN 664360-77-4 CAPLUS
CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-79-6 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-82-1 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethyl)phenyl]methyl]-, (α R,2S)- (CA INDEX NAME)

ACCESSION NUMBER: 2004:182855 CAPLUS
DOCUMENT NUMBER: 140:217649
TITLE: Preparation of aryl and heteroaryl morpholine derivatives as norepinephrine reuptake inhibitors
INVENTOR(S): Cases-Thomas, Manuel Javier; Haughton, Helen Louise; Lamas-Peteira, Carlos; Ouwerkerk-Mahadevan, Sivi; Masters, John Joseph; Simmonds, Robin George; Rudyk, Helene Catherine Eugenie; Walter, Magnus Wilhelm
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXKD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018441	A1	20040304	WO 2003-US23270	20030818
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003268024	A1	20040311	AU 2003-268024	20030818
EP 1534694	A1	20050601	EP 2003-748975	20030818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006003998	A1	20060105	US 2005-524921	20050215
PRIORITY APPLN. INFO.:				GB 2002-19687 A 20020823
				US 2002-415303P P 20021001
				WO 2003-US23270 W 20030818

OTHER SOURCE(S): MARPAT 140:217649
GI



AB Morpholine derivs. of formula I [R = independently H, alkyl; R1 = H, alkyl; Y = OH, alkoxy; Ar1, Ar2 = (substituted) Ph, (substituted) heteroaryl] are prepared. The compds. are selective inhibitors of the reuptake of norepinephrine. Thus, II.HCl was prepared from (4-benzylmorpholin-2-yl)-phenylmethanone (preparation given) and 2-(trifluoromethoxy)benzyl bromide. The compds. had Ki values less than 500 nM at the norepinephrine transporter in a scintillation proximity assay.


IT 664360-97-8P 664360-98-9P 664360-99-0P
664361-00-6P 664361-01-7P 664361-02-8P
664361-03-9P 664361-04-0P 664361-05-1P
664361-06-2P 664361-09-5P

RI: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(preparation of aryl and heteroaryl morpholine derivs. as norepinephrine reuptake inhibitors)

RN 664360-97-8 CAPLUS
CN 2-Morpholinemethanol, α -[(4'-methyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 664360-98-9 CAPLUS
CN 2-Morpholinemethanol, α -[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 664361-02-8 CAPLUS
CN 2-Morpholinemethanol, α -[(3'-methoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-03-9 CAPLUS
CN 2-Morpholinemethanol, α -[(3'-methyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-04-0 CAPLUS
CN 2-Morpholinemethanol, α -[(3',5'-dichloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664360-99-0 CAPLUS
CN 2-Morpholinemethanol, α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-00-6 CAPLUS
CN 2-Morpholinemethanol, α -[(3'-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-01-7 CAPLUS
CN 2-Morpholinemethanol, α -[(3'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-05-1 CAPLUS
CN 2-Morpholinemethanol, α -[(2',4'-dimethyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-06-2 CAPLUS
CN 2-Morpholinemethanol, α -[(2',4'-dimethoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664361-09-5 CAPLUS
CN 2-Morpholinemethanol, α -[(3',4'-dichloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 664361-41-5P


RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(preparation of aryl and heteroaryl morpholine derivs. as norepinephrine reuptake inhibitors)

RN 664361-41-5 CAPLUS

CN 2-Morpholinemethanol, α-phenyl-α-[[2-(trifluoromethyl)phenyl]methyl]-, (αR,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 664360-82-1P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aryl and heteroaryl morpholine derivs. as norepinephrine reuptake inhibitors)

RN 664360-82-1 CAPLUS

CN 2-Morpholinemethanol, α-phenyl-α-[[2-(trifluoromethyl)phenyl]methyl]-, (αR,2S)- (CA INDEX NAME)

Absolute stereochemistry.

664361-39-1P 664361-40-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aryl and heteroaryl morpholine derivs. as norepinephrine reuptake inhibitors)

RN 664360-72-9 CAPLUS

CN 2-Morpholinemethanol, α-[(2-methoxyphenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-73-0 CAPLUS

CN 2-Morpholinemethanol, α-[(2-ethoxyphenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-74-1 CAPLUS

CN 2-Morpholinemethanol, α-[[2-(1-methylethoxy)phenyl]methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 664360-79-6P 664361-42-6P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of aryl and heteroaryl morpholine derivs. as norepinephrine reuptake inhibitors)

RN 664360-79-6 CAPLUS

CN 2-Morpholinemethanol, α-[(5-fluoro-2-methoxyphenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664361-42-6 CAPLUS

CN 2-Morpholinemethanol, α-[(5-fluoro-2-hydroxyphenyl)methyl]-α-phenyl-, (αR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 664360-72-9P 664360-73-0P 664360-74-1P

664360-75-2P 664360-76-3P 664360-77-4P

664360-84-3P 664360-88-7P 664360-89-8P

664360-96-7P 664361-37-9P 664361-38-0P




● HCl

RN 664360-75-2 CAPLUS

CN 2-Morpholinemethanol, α-(3-fluorophenyl)-α-[(2-methoxyphenyl)methyl]-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-76-3 CAPLUS

CN 2-Morpholinemethanol, α-phenyl-α-[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-77-4 CAPLUS
 CN 2-Morpholinemethanol, α-([1,1'-biphenyl]-2-ylmethyl)-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 664360-84-3 CAPLUS
 CN 2-Morpholinemethanol, α-[(2-methylphenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-88-7 CAPLUS
 CN 2-Morpholinemethanol, α-[(2'-chloro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)




● HCl

RN 664361-37-9 CAPLUS
 CN 2-Morpholinemethanol, α-phenyl-α-[[2-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)





RN 664361-38-0 CAPLUS
 CN 2-Morpholinemethanol, α-phenyl-α-[[2-(trifluoromethoxy)phenyl]methyl]-, (αR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-39-1 CAPLUS
 CN 2-Morpholinemethanol, α-[(5-fluoro-2-methoxyphenyl)methyl]-α-phenyl- (CA INDEX NAME)



● HCl

RN 664360-89-8 CAPLUS
 CN 2-Morpholinemethanol, α-[(5-fluoro-2-hydroxyphenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-96-7 CAPLUS
 CN 2-Morpholinemethanol, α-[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 664361-40-4 CAPLUS
 CN 2-Morpholinemethanol, α-[(5-fluoro-2-methoxyphenyl)methyl]-α-phenyl-, (αR,2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
54.98	429.58

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-8.00	-8.00

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 12:15:50 ON 14 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 FEB 2008 HIGHEST RN 1003293-96-6
DICTIONARY FILE UPDATES: 13 FEB 2008 HIGHEST RN 1003293-96-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of

```

ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-12  7-8  8-9  9-10  10-11  11-12
exact/norm bonds :
1-2  1-6  1-14  2-3  2-18  3-4  3-19  4-5  5-6  5-21  6-20  7-17  15-16  15-17
15-21  15-26  26-27
normalized bonds :
7-12  7-8  8-9  9-10  10-11  11-12
isolated ring systems :
containing 1 : 7 :

```

```

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 26:CLASS 27:CLASS

```

L10 STRUCTURE UPLOADED



```

=> d
L10 HAS NO ANSWERS
L10                STR

```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structureattributes must be viewed using STN Express query preparation.



```

chain nodes :
14 15 16 17 18 19 20 21 26 27
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-14 2-18 3-19 5-21 6-20 7-17 15-16 15-17 15-21 15-26 26-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-12 7-8 8-9 9-10 10-11 11-12
exact/norm bonds :
1-2 1-6 1-14 2-3 2-18 3-4 3-19 4-5 5-6 5-21 6-20 7-17 15-16 15-17
15-21 15-26 26-27
normalized bonds :
7-12 7-8 8-9 9-10 10-11 11-12

```

```
=> s l13 full
FULL SEARCH INITIATED 12:20:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 18294 TO ITERATE
```

```
100.0% PROCESSED 18294 ITERATIONS 28 ANSWERS
SEARCH TIME: 00.00.01
```


```
L15 28 SEA SSS FUL L13
```

```
=> s l15 and caplus/lc
56059609 CAPLUS/LC
L16 23 L15 AND CAPLUS/LC
```

```
=> s l15 not l16
L17 5 L15 NOT L16
```


```
=> d l17 1-5
```


L17 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-23-3 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -(tetrahydro-2H-pyran-4-yl)- α -[[2-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)
 MF C18 H24 F3 N O4
 CI CCM
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L17 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-22-2 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -cyclopentyl- α -[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]- (CA INDEX NAME)
 MF C23 H28 F N O2
 CI CCM
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L17 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-20-0 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -cyclopentyl- α -[[2-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)
 MF C18 H24 F3 N O3
 CI CCM
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L17 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-19-7 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -cyclopentyl- α -[(2-ethoxyphenyl)methyl]- (CA INDEX NAME)
 MF C19 H29 N O3
 CI CCM
 SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L17 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2008 ACS on STN
RN 852431-18-6 REGISTRY
ED Entered STN: 17 Jun 2005
CN 2-Morpholinemethanol, α -cyclopentyl- α -[(5-fluoro-2-methoxyphenyl)methyl]- (CA INDEX NAME)
MF C18 H26 F N O3
CI CCM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> fil caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	374.63	804.21
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		
CA SUBSCRIBER PRICE	0.00	-8.00

FILE 'CAPLUS' ENTERED AT 12:20:45 ON 14 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Feb 2008 VOL 148 ISS 7
FILE LAST UPDATED: 13 Feb 2008 (20080213/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 12:12:41 ON 14 FEB 2008)

FILE 'REGISTRY' ENTERED AT 12:12:55 ON 14 FEB 2008

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 0 S L1 FULL

FILE 'STNGUIDE' ENTERED AT 12:13:41 ON 14 FEB 2008

FILE 'REGISTRY' ENTERED AT 12:14:21 ON 14 FEB 2008

L4 STRUCTURE UPLOADED
L5 7 S L4
L6 159 S L4 FULL
L7 119 S L6 AND CAPLUS/LC
L8 40 S L6 NOT L7

FILE 'CAPLUS' ENTERED AT 12:15:15 ON 14 FEB 2008

L9 10 S L7

FILE 'REGISTRY' ENTERED AT 12:15:50 ON 14 FEB 2008

L10 STRUCTURE UPLOADED
L11 1 S L10

L12 28 S L10 FULL
L13 STRUCTURE UPLOADED
L14 1 S L13
L15 28 S L13 FULL
L16 23 S L15 AND CAPLUS/LC
L17 5 S L15 NOT L16

FILE 'CAPLUS' ENTERED AT 12:20:45 ON 14 FEB 2008

=> s l16

L18 4 L16

=> d ibib abs hitstr 1-4

L18 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:95116 CAPLUS
TITLE: Biomarker-optimized attention deficit-hyperactivity disorder (ADHD) treatment with selective norepinephrine reuptake inhibitors
INVENTOR(S): Lawrence, Donald Gilbert
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 8pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2008020387	A1	20080124	US 2007-694099	20070330
PRIORITY APPLN. INFO.:			US 2006-788008P	P 20060331


AB The invention provides methods for predicting patient responsiveness to treatment of attention-deficit/hyperactivity disorder (ADHD) with selective norepinephrine reuptake inhibitors; identifying individuals requiring a higher than normal dose of atomoxetine for treating ADHD; and predicting patient responsiveness to treatment of neuropsychiatric diseases or disorders responsive to treatment with selective norepinephrine reuptake inhibitors are provided. These methods are based on the identification of the variable number of tandem repeats (VNTR) polymorphism present in the 3'-untranslated region of the human dopamine transporter 1 (DAT 1) gene present in patient body fluid or tissue samples. Patients with a 10/10 VNTR genotype are considered poor responders to treatment with atomoxetine and other selective norepinephrine reuptake inhibitors for the indicated conditions.

IT 852236-82-9 852237-54-8 852237-54-8D, salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biomarker-optimized attention deficit-hyperactivity disorder and neuropsychiatric disorder treatment with selective norepinephrine reuptake inhibitors)

RN 852236-82-9 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1), (α R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.


L18 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl


RN 852237-54-8 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(tetrahydro-2H-pyran-4-yl)-, (α R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 852237-54-8 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(tetrahydro-2H-pyran-4-yl)-, (α R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



L18 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


L18 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1331209 CAPLUS
DOCUMENT NUMBER: 146:223523
TITLE: Synthesis of ^{11}C -labelled (R)-OHDMI and CFMME and their evaluation as candidate radioligands for
imaging central norepinephrine transporters with PET
AUTHOR(S): Schou, Magnus; Pike, Victor W.; Sovago, Judit; Gulyas, Balazs; Gallagher, Peter T.; Dobson, David R.; Walter, Magnus W.; Rudyk, Helene; Farde, Lars; Halldin, Christer
CORPORATE SOURCE: Karolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Karolinska Hospital,
SOURCE: Stockholm, S-17176, Swed. Bioorganic & Medicinal Chemistry (2007), 15(2), 616-625
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:223523

AB (R)-1-(10,11-Dihydro-dibenzo[b,f]azepin-5-yl)-3-methylamino-propan-2-ol ((R)-OHDMI) and (S,S)-1-cyclopentyl-2-(5-fluoro-2-methoxy-phenyl)-1-morpholin-2-yl-ethanol (CFMME) were synthesized and found to be potent inhibitors of norepinephrine reuptake. Each was labeled efficiently in its Me group with carbon-11 ($t_{1/2}$ = 20.4 min) as a prospective radioligand for imaging brain norepinephrine transporters (NET) with positron emission tomog. (PET). The uptake and distribution of radioactivity in brain following i.v. injection of each radioligand into cynomolgus monkey was examined in vivo with PET. After injection of (R)-[^{11}C]OHDMI, the maximal whole brain uptake of radioactivity was very low (1.1% of injected dose; I.D.). For occipital cortex, thalamus, lower brainstem, mesencephalon and cerebellum, radioactivity ratios to striatum at 93 min after radioligand injection were 1.35, 1.35, 1.2, 1.2 and 1.0, resp. After injection of [^{11}C]CFMME, radioactivity readily entered brain (3.5% I.D.). Ratios of radioactivity to cerebellum at 93 min for thalamus, occipital cortex, region of locus coeruleus, mesencephalon and striatum were 1.35, 1.3, 1.2 and 1.2, resp. Radioactive metabolites in plasma were measured by radio-HPLC. (R)-[^{11}C]OHDMI represented 75% of plasma radioactivity at 4 min after injection and 6% at 30 min. After injection of [^{11}C]CFMME, 84% of the radioactivity in plasma represented parent at 4 min and 20% at 30 min. Since the two new hydroxylated radioligands provide only modest regional differentiation in brain uptake and form potentially troublesome lipophilic radioactive metabolites, they are concluded to be inferior to existing radioligands, such as (S,S)-[^{11}C]MeNER, (S,S)-[^{18}F]FMENER-D2 and (S,S)-[^{18}F]FRB-D4, for the study of brain NETs with PET in vivo.

IT 925232-43-5P
RL: DGN (Diagnostic use); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of ^{11}C -labeled (R)-OHDMI and CFMME as candidate radioligands for PET imaging of central norepinephrine transporters)


L18 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 925232-43-5 CAPLUS
CN 2-Morpholinemethanol, α -cyclopentyl- α -[5-fluoro-2-(methoxy-11C)-phenyl]methyl]-, (α S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 925232-42-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 11C-labeled (R)-OHDMI and CFMME as candidate radioligands for PET imaging of central norepinephrine transporters)
RN 925232-42-4 CAPLUS
CN 2-Morpholinemethanol, α -cyclopentyl- α -[5-fluoro-2-hydroxyphenyl]methyl]-, (α S,2S)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L18 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:588645 CAPLUS
DOCUMENT NUMBER: 143:115550
TITLE: Preparation of heterocyclic compounds as selective norepinephrine reuptake inhibitors for treating hot flashes, impulse control disorders and personality change due to a general medical condition
INVENTOR(S): Allen, Albert John; Hemrick-Luecke, Susan; Summer, Calvin Russell; Wallace, Owen Brendan
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 337 pp.
CODEN: PIXKD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060949	A2	20050707	WO 2004-US38221	20041201
WO 2005060949	A3	20050909		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2548304	A1	20050707	CA 2004-2548304	20041201
EP 1729754	A2	20061213	EP 2004-811076	20041201
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1889940	A	20070103	CN 2004-80036841	20041201
JP 2007513945	T	20070531	JP 2006-543830	20041201
US 2007015786	A1	20070118	US 2006-581015	20060530
PRIORITY APPLN. INFO.:				P 20031212
				WO 2004-US38221 W 20041201

OTHER SOURCE(S): MARPAT 143:115550
GI



AB The invention relates to a method of preventing or treating hot flashes,


L18 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
vasomotor symptoms, impulse control disorders or personality change due to a general medical condition, comprising administering to a patient in need thereof a therapeutically effective amt. of a selective norepinephrine reuptake inhibitor selected from atomoxetine, reboxetine, I [X = alkylthio; Y = alkyl], II [n = 1-3; R1 = alkyl, alkenyl, cycloalkyl, etc.; R2-R4 = H, alkyl, alkoxy, etc.; R5-R6 = H, alkyl, alkoxy, halo; R7-R8 = H, alkyl; R9-R10 = H, halo, OH, CN, alkyl, alkoxy], etc. Over 200 title compds. such as I, II and other heterocyclic compds. disclosed, were prepd. E.g., a 2-step synthesis of N-(2-methylpropyl)-N-[(2-fluorophenyl)methyl]piperidin-4-amine fumarate, starting from tert-Bu 4-(2-methylpropylamino)piperidine-1-carboxylate and 2-fluorobenzaldehyde, was given. The preferred exemplified title compds. exhibit a Ki value less than 1 μ M, more preferably less than 500 nM at the norepinephrine transporter as detd. using the scintillation proximity assay.
IT 852236-68-1P 852236-70-5P 852236-72-7P 852236-74-9P 852236-76-1P 852236-78-3P 852236-84-1P 852431-21-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as selective norepinephrine reuptake inhibitors for treating hot flashes, impulse control disorders and personality change due to general medical condition)
RN 852236-68-1 CAPLUS
CN 2-Morpholinemethanol, α -cyclopentyl- α -[5-fluoro-2-methoxyphenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-70-5 CAPLUS
CN 2-Morpholinemethanol, α -cyclopentyl- α -[2-ethoxyphenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




● HCl

RN 852236-72-7 CAPLUS
CN 2-Morpholinemethanol, α -cyclopentyl- α -[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-74-9 CAPLUS
CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -cyclopentyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-76-1 CAPLUS
CN 2-Morpholinemethanol, α -cyclopentyl- α -[4-fluoro[1,1'-

L18 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
biphenyl]-2-yl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-78-3 CAPLUS
CN 2-Morpholinemethanol, α-[(5-fluoro-2-methoxyphenyl)methyl]-α-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 852236-84-1 CAPLUS
CN 2-Morpholinemethanol, α-(tetrahydro-2H-pyran-4-yl)-α-[[2-(trifluoromethoxy)phenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

L18 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:451370 CAPLUS
DOCUMENT NUMBER: 142:482071
TITLE: Preparation of morpholine derivatives as norepinephrine reuptake inhibitors
INVENTOR(S): Campbell, Gordon Iain; Cases-Thomas, Manuel Javier; Man, Teresa; Masters, John Joseph; Rudyk, Helene Catherine Eugenie; Walter, Magnus Wilhelm
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005047272	A1	20050526	WO 2004-US32771	20041028
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004289616	A1	20050526	AU 2004-289616	20041028
CA 2544649	A1	20050526	CA 2004-2544649	20041028
EP 1682523	A1	20060726	EP 2004-794209	20041028
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
CN 1878762	A	20061213	CN 2004-80033115	20041028
BR 2004015273	A	20061219	BR 2004-15273	20041028
JP 2007510720	T	20070426	JP 2006-539492	20041028
US 2007083046	A1	20070412	US 2006-577841	20060429
MX 2006PA05226	A	20060720	MX 2006-PAS226	20060509
KR 783855	B1	20071210	KR 2006-708999	20060509
NO 2006002700	A	20060808	NO 2006-2700	20060612
PRIORITY APPLN. INFO.:			GB 2003-26148	A 20031110
			US 2004-535459P	P 20040109
			WO 2004-US32771	W 20041028

OTHER SOURCE(S): CASREACT 142:482071; MARPAT 142:482071
GI

L18 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 852431-21-1 CAPLUS
CN 2-Morpholinemethanol, α-([1,1'-biphenyl]-2-ylmethyl)-α-cyclopentyl- (CA INDEX NAME)




L18 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




AB Title compds. I [X = OH, alkoxy, NH₂, etc.; R independently = H, alkyl, with provisions; R₁ = (un)substituted-alkyl, -alkoxy, CN, etc.; R₂ = H, alkyl; R₃ = H, alkyl; Ar = (un)substituted-Ph, -5- to 6-membered heteroaryl] and their pharmaceutically acceptable salts, are prepared and disclosed as norepinephrine reuptake inhibitors. Thus, e.g., II was prepared by conversion of 4-benzyl-morpholine-2-carbonitrile into the resp. carboxylic Et ester followed by amidation with N,N-dimethylhydroxylamine and subsequent Grignard reactions with Me magnesium bromide and 2-phenylbenzyl magnesium bromide followed by debenzylation and conversion into the HCl salt. The activity of I was evaluated in a CYF2D6 inhibition assay and preferred compds. of the invention exhibited an IC₅₀ higher than 6 μM. I as norepinephrine reuptake inhibitors should prove useful in the treatment of disorders that are associated with norepinephrine dysfunction. Pharmaceutical compns. comprising I are disclosed.
IT 852236-82-9P
RL: IMP (Industrial manufacture); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of morpholine derivs. as norepinephrine reuptake inhibitors)
RN 852236-82-9 CAPLUS
CN 2-Morpholinemethanol, α-[(5-fluoro-2-methoxyphenyl)methyl]-α-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1), (αR,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.




● HCl

IT 852236-87-4P 852237-05-9P 852237-08-2P
 852237-11-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of morpholine derivs. as norepinephrine reuptake inhibitors)
 RN 852236-87-4 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 852237-05-9 CAPLUS
 CN 2-Morpholinemethanol, α -cyclopropyl- α -[(2-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 852237-08-2 CAPLUS
 CN 2-Morpholinemethanol, α -cyclopentyl- α -[(2-ethoxyphenyl)methyl]- (CA INDEX NAME)

L18 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN 2-Morpholinemethanol, α -cyclopentyl- α -[(2-ethoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-72-7 CAPLUS
 CN 2-Morpholinemethanol, α -cyclopentyl- α -[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 852236-74-9 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -cyclopentyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl



RN 852237-11-7 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -cyclopropyl- (CA INDEX NAME)



IT 852236-68-1P 852236-70-5P 852236-72-7P
 852236-74-9P 852236-76-1P 852236-78-3P
 852236-84-1P 852236-86-3P 852236-90-9P
 852237-04-8P 852237-07-1P 852237-10-6P
 852237-53-7P 852237-54-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of morpholine derivs. as norepinephrine reuptake inhibitors)
 RN 852236-68-1 CAPLUS
 CN 2-Morpholinemethanol, α -cyclopentyl- α -[(5-fluoro-2-methoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-70-5 CAPLUS


L18 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 852236-76-1 CAPLUS
 CN 2-Morpholinemethanol, α -cyclopentyl- α -[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-78-3 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(tetrahydro-2H-pyran-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-84-1 CAPLUS
 CN 2-Morpholinemethanol, α -(tetrahydro-2H-pyran-4-yl)- α -[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-86-3 CAPLUS
CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -(tetrahydro-2H-pyran-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-90-9 CAPLUS
CN 2-Morpholinemethanol, α -[(3'-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -(tetrahydro-2H-pyran-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852237-04-8 CAPLUS
CN 2-Morpholinemethanol, α -cyclopropyl- α -[(2-




● HCl

RN 852237-07-1 CAPLUS
CN 2-Morpholinemethanol, α -cyclopropyl- α -[(2-ethoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852237-10-6 CAPLUS
CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -cyclopropyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852237-53-7 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 852237-54-8 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(tetrahydro-2H-pyran-4-yl)-, (α R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 852236-91-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of morpholine derivs. as norepinephrine reuptake inhibitors)

RN 852236-91-0 CAPLUS
CN 2-Morpholinemethanol, α -[(3'-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
22.76	826.97

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-3.20	-11.20

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 12:21:40 ON 14 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 FEB 2008 HIGHEST RN 1003293-96-6
DICTIONARY FILE UPDATES: 13 FEB 2008 HIGHEST RN 1003293-96-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of

```

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-12 7-8 8-9 9-10 10-11 11-12
exact/norm bonds :
1-2 1-6 1-14 2-3 2-18 3-4 3-19 4-5 5-6 5-21 6-20 7-17 15-16 15-17
15-21 15-26 26-27
normalized bonds :
7-12 7-8 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

```

```

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 26:CLASS 27:CLASS

```

L19 STRUCTURE UPLOADED

```

=> d
L19 HAS NO ANSWERS
L19                STR

```



FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 16524 TO 20156
PROJECTED ANSWERS: 8 TO 329

L20 8 SEA SSS SAM L19

=> s 119 full
FULL SEARCH INITIATED 12:22:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 18294 TO ITERATE

100.0% PROCESSED 18294 ITERATIONS 196 ANSWERS
SEARCH TIME: 00.00.01

L21 196 SEA SSS FUL L19

=> s 121 and caplus
0 CAPLUS
L22 0 L21 AND CAPLUS


=> s 121 and caplus/lc
56059609 CAPLUS/LC
L23 136 L21 AND CAPLUS/LC

=> s 121 not 123
L24 60 L21 NOT L23

=> d 1241-60

L24 ANSWER 1 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 884512-45-2 REGISTRY
 ED Entered STN: 16 May 2006
 CN 2-Morpholinemethanol, α -(3-chlorophenyl)- α -(4-methoxybutyl)-,
 (6R,2R)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C16 H24 Cl N O3
 CI CCM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 2 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 857729-26-1 REGISTRY
 ED Entered STN: 31 Jul 2005
 CN 2-Morpholinemethanol, α -[(2'-chloro[1,1'-biphenyl]-2-yl)methyl]-
 α -phenyl-, (6R,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H24 Cl N O2
 CI CCM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 3 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 857729-25-0 REGISTRY
 ED Entered STN: 31 Jul 2005
 CN 2-Morpholinemethanol, α -[(2-fluorophenyl)methyl]- α -phenyl-,
 (6R,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H20 F N O2
 CI CCM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 4 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 857729-24-9 REGISTRY
 ED Entered STN: 31 Jul 2005
 CN 2-Morpholinemethanol, α -phenyl- α -(phenylmethyl)-,
 (6R,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H21 N O2
 CI CCM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 5 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 857729-23-8 REGISTRY
 ED Entered STN: 31 Jul 2005
 CN 2-Morpholinemethanol, α -[(2-methylphenyl)methyl]- α -phenyl-,
 (aR,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 H23 N O2
 CI CCM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 6 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 857729-22-7 REGISTRY
 ED Entered STN: 31 Jul 2005
 CN 2-Morpholinemethanol, α -[(2-chlorophenyl)methyl]- α -(3-fluorophenyl)-, (aR,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H19 Cl F N O2
 CI CCM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 7 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 857729-21-6 REGISTRY
 ED Entered STN: 31 Jul 2005
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -phenyl-, (aR,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 H22 F N O3
 CI CCM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 8 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 857729-20-5 REGISTRY
 ED Entered STN: 31 Jul 2005
 CN 2-Morpholinemethanol, α -[(2-chlorophenyl)methyl]- α -phenyl-, (aR,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H20 Cl N O2
 CI CCM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 9 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 857729-19-2 REGISTRY
 ED Entered STN: 31 Jul 2005
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -phenyl-, (α R,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H25 N O2
 CI CCM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 10 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 857729-18-1 REGISTRY
 ED Entered STN: 31 Jul 2005
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethoxy)phenyl]methyl]-, (α R,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 H20 F3 N O3
 CI CCM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 11 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 857729-17-0 REGISTRY
 ED Entered STN: 31 Jul 2005
 CN 2-Morpholinemethanol, α -(3-fluorophenyl)- α -[[2-methoxyphenyl]methyl]-, (α R,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 H22 F N O3
 CI CCM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 12 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 857729-16-9 REGISTRY
 ED Entered STN: 31 Jul 2005
 CN 2-Morpholinemethanol, α -[[2-(1-methylethoxy)phenyl]methyl]- α -phenyl-, (α R,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C21 H27 N O3
 CI CCM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 13 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 857729-15-8 REGISTRY
 ED Entered STN: 31 Jul 2005
 CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -phenyl-,
 (aR,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C20 H25 N O3
 CI CCM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 14 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 857729-14-7 REGISTRY
 ED Entered STN: 31 Jul 2005
 CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -phenyl-,
 (aR,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 H23 N O3
 CI CCM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 15 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 857642-47-8 REGISTRY
 ED Entered STN: 29 Jul 2005
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-
 [(trifluoromethyl)thio]phenyl]methyl]-, (aR,2S)-rel- (CA INDEX
 NAME)
 FS STEREOSEARCH
 MF C19 H20 F3 N O2 S
 CI CCM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 16 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 854302-51-5 REGISTRY
 ED Entered STN: 10 Jul 2005
 CN 2-Morpholinemethanol, α -[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]-
 α -phenyl-, (aR,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H24 F N O2
 CI CCM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 17 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 854302-50-4 REGISTRY
 ED Entered STN: 10 Jul 2005
 CN 2-Morpholinemethanol, α -[(2,5-difluorophenyl)methyl]- α -phenyl-
 , (6R,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H19 F2 N O2
 CI CCM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 18 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 854302-49-1 REGISTRY
 ED Entered STN: 10 Jul 2005
 CN 2-Morpholinemethanol, α -[(2,5-dichlorophenyl)methyl]- α -phenyl-
 , (6R,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H19 Cl2 N O2
 CI CCM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 19 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 854302-48-0 REGISTRY
 ED Entered STN: 10 Jul 2005
 CN 2-Morpholinemethanol, α -[(2,6-dichlorophenyl)methyl]- α -phenyl-
 , (6R,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H19 Cl2 N O2
 CI CCM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 20 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 854302-47-9 REGISTRY
 ED Entered STN: 10 Jul 2005
 CN 2-Morpholinemethanol, α -[(2,4-difluorophenyl)methyl]- α -phenyl-
 , (6R,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H19 F2 N O2
 CI CCM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 21 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 854302-46-8 REGISTRY
 ED Entered STN: 10 Jul 2005
 CN 2-Morpholinemethanol, α -[(2,5-dimethoxyphenyl)methyl]- α -phenyl-, (α R,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C20 H25 N O4
 CI CCM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L24 ANSWER 22 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 854302-45-7 REGISTRY
 ED Entered STN: 10 Jul 2005
 CN 2-Morpholinemethanol, α -[(2-chloro-6-fluorophenyl)methyl]- α -phenyl-, (α R,2S)-rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H19 Cl F N O2
 CI CCM
 SR CA

Relative stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 23 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-33-5 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -[(2-chlorophenyl)methyl]- α -(2-methylpropyl)- (CA INDEX NAME)
 MF C16 H24 Cl N O2
 CI CCM
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 24 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-32-4 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -[(2-chloro-6-fluorophenyl)methyl]- α -(2-methylpropyl)- (CA INDEX NAME)
 MF C16 H23 Cl F N O2
 CI CCM
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 25 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-31-3 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -butyl-
 (CA INDEX NAME)
 MF C22 H29 N O2
 CI CCM
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 26 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-30-2 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -butyl- α -[(2-methoxyphenyl)methyl]-
 (CA INDEX NAME)
 MF C17 H27 N O3
 CI CCM
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 27 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-28-8 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α , α -bis[(2-methoxyphenyl)methyl]- (CA
 INDEX NAME)
 MF C21 H27 N O4
 CI CCM
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 28 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-27-7 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -
 (4,4,4-trifluorobutyl)- (CA INDEX NAME)
 MF C17 H23 F4 N O3
 CI CCM
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 29 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-26-6 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -(3,3,3-trifluoropropyl)- (CA INDEX NAME)
 MF C21 H24 F3 N O2
 CI CCM
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 30 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-25-5 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -[2-(trifluoromethoxy)phenylmethyl]- α -(3,3,3-trifluoropropyl)- (CA INDEX NAME)
 MF C16 H19 F6 N O3
 CI CCM
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 31 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-24-4 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(3,3,3-trifluoropropyl)- (CA INDEX NAME)
 MF C16 H21 F4 N O3
 CI CCM
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 32 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-17-5 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -(2-methylpropyl)- α -[2-(trifluoromethoxy)phenylmethyl]- (CA INDEX NAME)
 MF C17 H24 F3 N O3
 CI CCM
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 33 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-16-4 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(2-methylpropyl)- (CA INDEX NAME)
 MF C17 H26 F N O3
 CI CCM
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 34 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-15-3 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -(1-methylethyl)- (CA INDEX NAME)
 MF C21 H26 F N O2
 CI CCM
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 35 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-14-2 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -(1-methylethyl)- (CA INDEX NAME)
 MF C21 H27 N O2
 CI CCM
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 36 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-13-1 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -(1-methylethyl)- α -[2-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)
 MF C16 H22 F3 N O3
 CI CCM
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 37 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-12-0 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(1-methylethyl)- (CA INDEX NAME)
 MF C16 H24 F N O3
 CI CCM
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 38 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-11-9 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -ethyl- (CA INDEX NAME)
 MF C20 H25 N O2
 CI CCM
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 39 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-10-8 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -ethyl- α -[2-(trifluoromethoxy)phenylmethyl]- (CA INDEX NAME)
 MF C15 H20 F3 N O3
 CI CCM
 SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 40 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-09-5 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -ethyl- α -[(5-fluoro-2-methoxyphenyl)methyl]- (CA INDEX NAME)
 MF C15 H22 F N O3
 CI CCM
 SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L24 ANSWER 41 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 852431-08-4 REGISTRY
 ED Entered STN: 17 Jun 2005
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -methyl-
 (CA INDEX NAME)
 MF C19 H23 N O2
 CI CCM
 SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 42 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 793666-65-6 REGISTRY
 ED Entered STN: 07 Dec 2004
 CN 2-Morpholinemethanol, α -[(2-chlorophenyl)methyl]- α -phenyl-,
 (aR,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H20 Cl N O2
 CI CCM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 43 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 790207-20-4 REGISTRY
 ED Entered STN: 29 Nov 2004
 CN 2-Morpholinemethanol, α -[(2-chlorophenyl)methyl]- α -(3-fluorophenyl)-, (aR,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H19 Cl F N O2
 CI CCM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 44 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 788156-38-7 REGISTRY
 ED Entered STN: 25 Nov 2004
 CN 2-Morpholinemethanol, α -(3-fluorophenyl)- α -[(2-methoxyphenyl)methyl]-, (aR,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 H22 F N O3
 CI CCM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 45 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 785047-43-0 REGISTRY
 ED Entered STN: 21 Nov 2004
 CN 2-Morpholinemethanol, α -[(2,6-dichlorophenyl)methyl]- α -phenyl-,
 (aR,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H19 Cl2 N O2
 CI CCM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 46 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 760944-34-1 REGISTRY
 ED Entered STN: 12 Oct 2004
 CN 2-Morpholinemethanol, α -[(2-fluorophenyl)methyl]- α -phenyl-,
 (aR,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H20 F N O2
 CI CCM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 47 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 760172-63-2 REGISTRY
 ED Entered STN: 11 Oct 2004
 CN 2-Morpholinemethanol, α -[(2'-chloro[1,1'-biphenyl]-2-yl)methyl]-
 α -phenyl-, (aR,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H24 Cl N O2
 CI CCM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 48 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 758684-59-2 REGISTRY
 ED Entered STN: 08 Oct 2004
 CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -phenyl-,
 (aR,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C20 H25 N O3
 CI CCM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 49 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
RN 757940-98-0 REGISTRY
ED Entered STN: 07 Oct 2004
CN 2-Morpholinemethanol, α -[(2-methylphenyl)methyl]- α -phenyl-,
($\alpha R, 2S$)- (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H23 N O2
CI CCM
SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 50 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
RN 756475-53-3 REGISTRY
ED Entered STN: 04 Oct 2004
CN 2-Morpholinemethanol, α -[(2,4-difluorophenyl)methyl]- α -phenyl-,
($\alpha R, 2S$)- (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H19 F2 N O2
CI CCM
SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 51 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
RN 752982-94-8 REGISTRY
ED Entered STN: 28 Sep 2004
CN 2-Morpholinemethanol, α -[(2,5-dichlorophenyl)methyl]- α -phenyl-,
($\alpha R, 2S$)- (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H19 Cl2 N O2
CI CCM
SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 52 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
RN 752201-49-3 REGISTRY
ED Entered STN: 27 Sep 2004
CN 2-Morpholinemethanol, α -[(2,5-dimethoxyphenyl)methyl]- α -phenyl-,
($\alpha R, 2S$)- (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H25 N O4
CI CCM
SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 53 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 750570-01-5 REGISTRY
 ED Entered STN: 24 Sep 2004
 CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -phenyl-,
 (aR,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 H23 N O3
 CI CCM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 54 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 747409-08-1 REGISTRY
 ED Entered STN: 19 Sep 2004
 CN 2-Morpholinemethanol, α -phenyl- α -(phenylmethyl)-,
 (aR,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H21 N O2
 CI CCM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 55 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 744196-20-1 REGISTRY
 ED Entered STN: 14 Sep 2004
 CN 2-Morpholinemethanol, α -[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]-
 α -phenyl-, (aR,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H24 F N O2
 CI CCM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 56 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 743418-65-7 REGISTRY
 ED Entered STN: 13 Sep 2004
 CN 2-Morpholinemethanol, α -[(2,5-difluorophenyl)methyl]- α -phenyl-,
 (aR,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H19 F2 N O2
 CI CCM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 57 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 736926-30-0 REGISTRY
 ED Entered STN: 01 Sep 2004
 CN 2-Morpholinemethanol, α -[(2-chloro-6-fluorophenyl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H19 Cl F N O2
 CI CCM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 58 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 732983-60-7 REGISTRY
 ED Entered STN: 26 Aug 2004
 CN 2-Morpholinemethanol, α -[[2-(1-methylethoxy)phenyl]methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C21 H27 N O3
 CI CCM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 59 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 701907-86-0 REGISTRY
 ED Entered STN: 30 Jun 2004
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -phenyl-, (α R,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H25 N O2
 CI CCM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 ANSWER 60 OF 60 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 664360-80-9 REGISTRY
 ED Entered STN: 18 Mar 2004
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-[(trifluoromethyl)thio]phenyl]methyl]-, (α R,2S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 H20 F3 N O2 S
 CI CCM
 SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> fil caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	309.58	1136.55
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-11.20

FILE 'CAPLUS' ENTERED AT 12:23:15 ON 14 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Feb 2008 VOL 148 ISS 7
FILE LAST UPDATED: 13 Feb 2008 (20080213/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.

L12 28 S L10 FULL
L13 STRUCTURE UPLOADED
L14 1 S L13
L15 28 S L13 FULL
L16 23 S L15 AND CAPLUS/LC
L17 5 S L15 NOT L16

FILE 'CAPLUS' ENTERED AT 12:20:45 ON 14 FEB 2008
L18 4 S L16

FILE 'REGISTRY' ENTERED AT 12:21:40 ON 14 FEB 2008
L19 STRUCTURE UPLOADED
L20 8 S L19
L21 196 S L19 FULL
L22 0 S L21 AND CAPLUS
L23 136 S L21 AND CAPLUS/LC
L24 60 S L21 NOT L23

FILE 'CAPLUS' ENTERED AT 12:23:15 ON 14 FEB 2008

=> s l23
L25 14 L23


=> d ibib abs hitstr 1-14

L25 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1177123 CAPLUS
DOCUMENT NUMBER: 147:469237
TITLE: Acylpiperidine compounds as renin inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases associated with aspartic protease activity
INVENTOR(S): Baldwin, John J.; Claremon, David A.; Tice, Colin M.; Caccatian, Salvacion; Dillard, Lawrence W.; Ishchenko, Alexey V.; Yuan, Jing; Xu, Zhenrong; Mcgeehan, Gerard; Zhao, Wei; Simpson, Robert D.; Singh, Suresh B.; Flaherty, Patrick T.; Kallander, Lara S.; Leach, Colin A.; Lawhorn, Brian; Lu, Qing; Terrell, Lamont R.; Ghavini-Alagha, Bahman; Zhang, Jing; Ghirlanda, Damiano; Hou, Xiaoping; Semus, Simon
PATENT ASSIGNEE(S): Vitae Pharmaceuticals, Inc., USA; Smithkline Beecham Corporation
SOURCE: PCT Int. Appl., 619pp.
DOCUMENT TYPE: CODEN: PIXXD2
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: English
PATENT INFORMATION: 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007117482	A2	20071018	WO 2007-US8339	20070405
WO 2007117482	A3	20071122		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
PRIORITY APPLN. INFO.: US 2006-789703P P 20060405				
US 2006-789823P P 20060405				


OTHER SOURCE(S): MARPAT 147:469237
GI

L25 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




AB Disclosed are compds. according to formula I: wherein the variables are defined herein. Compds. of formula I wherein R is H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, etc.; R1 is (un)substituted Ph, (un)substituted (mono/bi)cyclic heteroaryl and (un)substituted C3-7 cycloalkyl; X and Y are independently CH2 and a single bond; R2 is H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-12 alkoxy, etc.; R3 is H, halo, C1-6 alkyl, C1-6 alkoxy, OH, etc.; A is (un)substituted (un)saturated (un)bridge 4- to 7-membered ring; Q and Y are attached to carbon or nitrogen in ring A via 1,2- or 1,3- or 1,4-relationship; Q is CO, CS, SO2, C=CH-NO2, C=N-CN, dioxocyclobutenylene, etc.; W is a bond and (un)substituted C1-5 alkylene; E is (un)substituted (un)saturated (un)bridge 3- to 7-membered ring; G is H, C1-6 alkyl, C4-7 heterocyclyl, OH, NH2 and derivs., etc.; and their enantiomers, diastereoisomers, and pharmaceutically acceptable salts thereof, are claimed. Such compds. are can bind aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described herein are methods of antagonizing aspartic protease inhibitors in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to formula I. Example compound II was prepared by a multistep procedure (procedure given).
All the invention compds. were evaluated for their renin inhibitory activity (some data given).
IT 952593-50-9P 952708-89-3P
R1: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of acylpiperidine compds. as aspartic protease inhibitors including renin inhibitors useful in treatment of diseases associated with aspartic protease activity)
RN 952593-50-9 CAPLUS
CN 2-Morpholinemethanol, α -(6-fluoro-3'-methyl[1,1'-biphenyl]-2-yl)- α -(4-methoxybutyl)-, (aR,2R)- (CA INDEX NAME)
Absolute stereochemistry.

L25 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 952708-89-3 CAPLUS
CN 2-Morpholinemethanol, α -3-buten-1-yl- α -(6-chloro-3'-ethyl[1,1'-biphenyl]-2-yl)-, (aR,2R)- (CA INDEX NAME)


Absolute stereochemistry.



L25 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1177123 CAPLUS
DOCUMENT NUMBER: 147:469236
TITLE: Piperidinyl pyrrolidinyl methanone compounds as renin inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases associated with aspartic protease activity
INVENTOR(S): Baldwin, John J.; Claremon, David A.; Tice, Colin M.; Caccatian, Salvacion; Dillard, Lawrence W.; Ishchenko, Alexey V.; Yuan, Jing; Xu, Zhenrong; Mcgeehan, Gerard; Zhao, Wei; Simpson, Robert D.; Singh, Suresh B.
PATENT ASSIGNEE(S): Vitae Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 328pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION: 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007117559	A2	20071018	WO 2007-US8520	20070405
WO 2007117559	A3	20071129		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
PRIORITY APPLN. INFO.: US 2006-789703P P 20060405				
US 2006-789823P P 20060405				

OTHER SOURCE(S): MARPAT 147:469236
GI



II

AB Described are compds. of formula I, which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compds. described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof. Compds. of formula I wherein R is C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-7 cycloalkyl, C2-7 cycloalkenyl, etc.; R1 is Ph, (mono/bi)cyclic heteroaryl, benzo-1,3-dioxole, benzo-1,3-dioxin, etc.; X and Y are independently CH2 and a single bond; R2 is H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-12 alkoxy, C1-12 alkylthio, etc.; R3 is H, halo, C1-6 alkyl, C1-6 alkoxy, OH, etc.; A is (un)substituted (un)saturated (un)bridge 4- to 7-membered ring; Q and U are attached to carbon or nitrogen atoms in ring A in a 1,2 or 1,3 or 1,4 relationship; Q is CO, CS, SO2, C=C-NO2, C=N-CN, dioxocyclobutylene, etc.; E is (un)substituted (un)saturated (un)bridge 3- to 7-membered ring; G is OH, C1-6 hydroxyalkyl, amino, C1-6 aminoalkyl, C(=NH)NH2 and derivs., etc.; and their enantiomers, diastereoisomers and salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given).

All the invention compds. were evaluated for their renin inhibitory activity.
 IT 952593-50-9P 952708-89-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of pyrrolidinyl piperidinyl methanone compds. as aspartic protease inhibitors including renin inhibitors useful in treatment of diseases - associated with aspartic protease activity)
 RN 952593-50-9 CAPLUS
 CN 2-Morpholinemethanol, α -(6-fluoro-3'-methyl[1,1'-biphenyl]-2-yl)- α -(4-methoxybutyl)-, (aR,2R)- (CA INDEX NAME)

Absolute stereochemistry.


L25 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:1175900 CAPLUS
 DOCUMENT NUMBER: 147:469351
 TITLE: Piperidines and morpholines as renin inhibitors and their preparation, pharmaceutical compositions and use
 in the treatment of diseases associated with renin activity
 INVENTOR(S): Baldwin, John J.; Claremon, David A.; Tice, Colin M.; Cacatian, Salvacion; Dillard, Lawrence W.; Ishchenko, Alexey V.; Yuan, Jing; Xu, Zhenrong; Mogeehan, Gerard;
 Zhao, Wei; Simpson, Robert D.; Singh, Suresh B.
 PATENT ASSIGNEE(S): Vitae Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 222pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007117560	A2	20071018	WO 2007-US8521	20070405
WO 2007117560	A3	20071206		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA



PRIORITY APPLN. INFO.: US 2006-789723P P 20060405

OTHER SOURCE(S): MARPAT 147:469351
 GI



RN 952708-89-3 CAPLUS
 CN 2-Morpholinemethanol, α -3-buten-1-yl- α -(6-chloro-3'-ethyl[1,1'-biphenyl]-2-yl)-, (aR,2R)- (CA INDEX NAME)



Absolute stereochemistry.



II

AB Described are compds. of formula I which are orally active and bind to renin to inhibit its activity. Compds. of formula I wherein G1 is C1-9 (halo)alkyl, C3-7 (halo)cycloalkyl, C4-9 (halo)cycloalkylalkyl, Ph, etc.; G2 is H, C1-8 (fluoro)alkyl, C4-8 (fluoro)cycloalkylalkyl, C1-8 (fluoro)alkoxy, etc.; G3 is H, halo, OH, C1-4 alkanoylamino, and C1-3 alkoxy; A4 is CH2 and O; Q is CO, CS, SO2, C=C-NO2, C=N-CN, COCO, etc.; T is a mimic of the Leu-Val cleavage site of angiotensinogen; and their enantiomers, diastereoisomers, and salts thereof, are claimed. They are useful in the treatment or amelioration of diseases associated with renin activity. Also described are methods of use of these compds. for treating or ameliorating a renin mediated disorder in a subject. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their renin inhibitory activity.
 IT 884528-24-9P 952593-47-4P 952593-50-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of piperidine and morpholine compds. as renin inhibitors useful in treatment of diseases - associated with aspartic protease and renin activity)
 RN 884528-24-9 CAPLUS
 CN 2-Morpholinemethanol, α -(3-chlorophenyl)- α -(4-methoxybutyl)-, (aR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



AB Described are diaminopropanols of formula I, which are orally active and bind to renin to inhibit its activity. Compds. of formula I wherein R1 is

C1-12 (halo)alkyl, C3-7 (halo)cycloalkyl, C4-12 (halo)cycloalkylalkyl, (un)substituted heterocyclyl, Ph, naphthyl, heteroaryl, etc.; X and Y are independently CH2, and a single bond; R2 is (un)substituted C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-12 alkoxy, C1-12 alkylthio, etc.; R3 is H, halo, C1-6 alkyl, C1-6 alkoxy, OH, C1-6 hydroxyalkyl, C1-6 hydroxyalkoxy, etc.; A is (un)substituted (un)saturated 4- to 7-membered ring;

Y and Q are attached to carbon or nitrogen atoms in ring A in 1,2 or 1,3, or 1,4 relationship; Q is CO, CS, SO2, C=CN02, C=N-CN, COCO, etc.; R4 is H, C1-6 (halo)alkyl, C1-3 alkoxy-C1-3 alkyl, and C1-6 cyanoalkyl; R5 is C1-12 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl-C1-3 alkyl, C2-12 alkenyl, etc.; R9 is H, C1-12 (halo)alkyl, C4-12 (halo)cycloalkyl, C2-12 alkenyl, etc.; and their enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof, are claimed. Compds. of formula I are useful in the treatment or amelioration of diseases associated with elevated levels of renin activity or in the treatment of aspartic protease mediated disorders. Also described is a method for the use of the diaminopropanols in ameliorating or treating renin related disorders in a subject in need thereof. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their renin inhibitory activity (some data given).

IT 352593-47-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of diaminopropanol derivs. as renin inhibitors useful in treatment or amelioration of diseases associated with elevated levels of renin activity or aspartic protease mediated disorders)

RN 352593-47-4 CAPLUS


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007117557	A2	200710118	WO 2007-US8518	20070405
WO 2007117557	A3	200711129		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, KE, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SI, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
FW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, CF, CG, CI, CM, CA, GN, QD, GM, ML, NR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRIORITY APPLN. INFO.:			US 2006-789713P	P 20060405
			US 2006-789789P	P 20060405
OTHER SOURCE(S):	MARPAT 147:469234			
GI				

L25 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:365001 CAPLUS
DOCUMENT NUMBER: 144:432692
TITLE: Preparation of diaminoalkanes, particularly
N-(1-aminopropan-2-yl)piperidine-1-carboxamides, as
aspartic protease inhibitors
INVENTOR(S): Baldwin, John J.; Claremon, David A.; Tice, Colin;
Cacatian, Salvation; Dillard, Lawrence W.; Ishchenko,
Alexey V.; Yuan, Jing; Xu, Zhenrong; McGeehan,
Gerard;
Zhao, Wei; Simpson, Robert D.; Singh, Suresh B.;
Flaherty, Patrick T.; Wery, Jean-Pierre
PATENT ASSIGNEE(S): Vitae Pharmaceutical, Inc, USA
SOURCE: PCT Int. Appl., 755 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006042150	A1	20060420	WO 2005-US36230	20051007
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2005294123	A1	20060420	AU 2005-294123	20051007
CA 2582202	A1	20060420	CA 2005-2582202	20051007
EP 1807078	A1	20070718	EP 2005-807547	20051007
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
CN 101072561	A	20071114	CN 2005-80042064	20051007
BR 2005016132	A	20071204	BR 2005-16132	20051007
KR 2007084040	A	20070824	KR 2007-710366	20051007
IN 2007CN01935	A	20070831	IN 2007-CN1935	20070507
PRIORITY APPLN. INFO.:			US 2004-616770P	P 20041007
			WO 2005-US36230	W 20051007

OTHER SOURCE(S): MARPAT 144:432692
GI

L25 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB The invention is related to diaminoalkanes of formula R1-X-(CR2R3)-Y-A-Q-N(R4)-L-G [I; R1 = halocyclo/cycloalkyl, (un)substituted Ph, naphthyl, heteroaryl, etc.; X, Y = independently CH2 or a single bond; R2 = (un)substituted alk(en/yn)yl, alkoxyalkyl, aminocarbonylaminoalkyl, aminosulfonylaminoalkyl, etc.; R3 = H, alkyl, OH and derivs., alkylaminosulfonylamino, (un)substituted phenylamino, heteroarylamino; A

= (un)saturated (un)substituted 4- to 7-membered ring, which is optionally bridged by (CH2)m via bonds to 2 members of said ring; Q and Y are attached to C or N atoms in ring A in a 1,2 or 1,3 or 1,4 relationship; Q = divalent radical selected from CO, C:S, SO2, CO-CO, CO-CH2-CO, etc.; m

= 1-3; R4 = H, halo/alkoxy/cyano/alkyl; L = (un)substituted linear (C2-C4)alkyl chain when G = OH, OR9, NH2, NHR9, NR9R10, NHC(:NH)NH2, or NHC(:NH)NHR9; or L = (un)substituted linear (C1-C3)alkyl chain when G = C(:NH)NH2, or C(:NH)NHR9; G = OH, OR9, NH2, NHR9, NR9R10, NHC(:NH)NH2, NHC(:NH)NHR9, C(:NH)NH2, C(:NH)NHR9; R9 = halo/alkyl, (un)substituted Ph, naphthyl, heteroaryl, heteroarylsulfinyl, naphthyl, etc.; R10 = halo/alkyl; with provisos;], and their enantiomers, diastereomers, and salts, e.g. II, which are orally active and bind to aspartic proteases to inhibit their activity. I are useful in the treatment or amelioration of diseases associated with elevated levels of aspartic protease activity. Thus, reacting benzyl N-((S)-2-amino-3-cyclohexylpropyl)-N-(2,2,2-trifluoroethyl)carbamate (preparation given) with

(1S)-1-(3-chlorophenyl)-5-methoxy-1-((3R)-piperidin-3-yl)pentan-1-ol and CDI in the presence of

DIEA in CH2Cl2, followed by Cbz-deprotection gave piperidine II. Selected I had an IC50 in the range of 0.001 nM to 5 nM for the inhibition of renin activity. I are useful in ameliorating or treating aspartic protease related disorders, such as hypertension, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, etc. cardiomyopathy postinfarction, nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels.

IT 884512-46-3p 884528-24-9p 884528-52-3p
RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of diaminoalkane aspartic protease inhibitors)

RN 884512-46-3 CAPLUS
CN 2-Morpholinemethanol, α -(3-chlorophenyl)- α -(4-methoxybutyl)-, (α R,2R)-rel-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

L25 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CRN 884512-45-2
CMP C16 H24 Cl N O3

Relative stereochemistry.




CM 2

CRN 76-05-1
CMP C2 H F3 O2



RN 884528-24-9 CAPLUS
CN 2-Morpholinemethanol, α -(3-chlorophenyl)- α -(4-methoxybutyl)-, (α R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 884528-52-3 CAPLUS
CN 2-Morpholinemethanol, α -(3-chloro-2-fluorophenyl)- α -(4-methoxybutyl)-, (α R)- (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L25 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:588645 CAPLUS
 DOCUMENT NUMBER: 143:115550
 TITLE: Preparation of heterocyclic compounds as selective norepinephrine reuptake inhibitors for treating hot flashes, impulse control disorders and personality change due to a general medical condition
 INVENTOR(S): Allen, Albert John; Hemrick-Luecke, Susan; Sumner, Calvin Russell; Wallace, Owen Brendan
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int., 337 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060949	A2	20050707	WO 2004-US38221	20041201
WO 2005060949	A3	20050909		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HT, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2548304	A1	20050707	CA 2004-2548304	20041201
EP 1729754	A2	20061213	EP 2004-811076	20041201
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 1889940	A	20070103	CN 2004-80036841	20041201
JP 2007513945	T	20070531	JP 2006-543830	20041201
US 2007015786	A1	20070118	US 2006-581015	20060530
PRIORITY APPLN. INFO.:			US 2003-529428P	P 20031212
			WO 2004-US38221	W 20041201

OTHER SOURCE(S): MARPAT 143:115550
 GI




L25 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 854139-89-2P 854139-90-5P 854139-91-6P
 857642-38-7P 857642-40-1P 857642-41-2P
 857642-42-3P 857642-43-4P 857642-44-5P
 857642-45-6P 857642-48-9P 857642-51-4P
 857642-52-5P 857642-54-7P 857642-56-9P
 857642-57-0P 857642-59-2P 857642-60-5P
 857642-61-6P 857642-62-7P 857642-63-8P
 857642-64-9P 857642-65-0P 857642-66-1P
 857642-67-2P 857642-68-3P 857642-69-4P
 857642-70-7P 857642-71-8P 857642-72-9P
 857642-73-0P 857642-74-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of heterocyclic compds. as selective norepinephrine reuptake inhibitors for treating hot flashes, impulse control disorders and personality change due to general medical condition)
 RN 664360-82-1 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethyl)phenyl]methyl]-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664361-41-5 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethyl)phenyl]methyl]-, (α R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 852236-27-2 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -methyl-, hydrochloride (9CI) (CA INDEX NAME)

L25 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB The invention relates to a method of preventing or treating hot flashes, vasomotor symptoms, impulse control disorders or personality change due to a general medical condition, comprising administering to a patient in need thereof a therapeutically effective amount of a selective norepinephrine reuptake inhibitor selected from atomoxetine, reboxetine, I [X = alkylthio; Y = alkyl], II [n = 1-3; R1 = alkyl, alkenyl, cycloalkyl, etc.; R2-R4 = H, alkyl, alkoxy, etc.; R5-R6 = H, alkyl, alkoxy, halo; R7-R8 = H, alkyl; R9-R10 = H, halo, OH, CN, alkyl, alkoxy], etc. Over 200 title compds. such as I, II and other heterocyclic compds. disclosed, were prepared E.g., a 2-step synthesis of N-(2-methylpropyl)-N-[(2-fluorophenyl)methyl]piperidin-4-amine fumarate, starting from tert-Bu 4-(2-methylpropylamino)piperidine-1-carboxylate and 2-fluorobenzaldehyde, was given. The preferred exemplified title compds. exhibit a Ki value less than 1 μ M, more preferably less than 500 nM at the norepinephrine transporter as determined using the scintillation proximity assay.
 IT 857642-46-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of heterocyclic compds. as selective norepinephrine reuptake inhibitors for treating hot flashes, impulse control disorders and personality change due to general medical condition)
 RN 857642-46-7 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


IT 664360-82-1P 664361-41-5P 852236-27-2P
 852236-29-4P 852236-31-8P 852236-33-0P
 852236-35-2P 852236-37-4P 852236-38-5P
 852236-39-6P 852236-40-9P 852236-42-1P
 852236-43-2P 852236-44-3P 852236-45-4P
 852236-47-6P 852236-49-8P 852236-51-2P
 852236-53-4P 852236-55-6P 852236-56-7P
 852236-58-9P 852236-60-3P 852236-63-6P
 852236-65-8P 852236-66-9P 854139-85-8P
 854139-86-9P 854139-87-0P 854139-88-1P

L25 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




● HCl

RN 852236-29-4 CAPLUS
 CN 2-Morpholinemethanol, α -ethyl- α -[(5-fluoro-2-methoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-31-8 CAPLUS
 CN 2-Morpholinemethanol, α -ethyl- α -[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-33-0 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -ethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-35-2 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(1-methylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-37-4 CAPLUS
CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -(1-methylethyl)-, (α R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 852236-39-5 CAPLUS
CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -(1-methylethyl)-, (α R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 852236-43-2 CAPLUS
CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -(1-methylethyl)-, (α R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 852236-44-3 CAPLUS
CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -(1-methylethyl)-, hydrochloride, (α R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 852236-45-4 CAPLUS
CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -(1-methylethyl)-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 852236-39-6 CAPLUS
CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -(1-methylethyl)-, hydrochloride, (α R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 852236-40-9 CAPLUS
CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -(1-methylethyl)-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 852236-42-1 CAPLUS
CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -(1-methylethyl)-, (α R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 852236-47-6 CAPLUS
CN 2-Morpholinemethanol, α -(1-methylethyl)- α -[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-49-8 CAPLUS
CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -(1-methylethyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-51-2 CAPLUS
CN 2-Morpholinemethanol, α -[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -(1-methylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-53-4 CAPLUS
CN 2-Morpholinemethanol, α-[(5-fluoro-2-methoxyphenyl)methyl]-α-(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 852236-55-6 CAPLUS
CN 2-Morpholinemethanol, α-[(2-ethoxyphenyl)methyl]-α-(2-methylpropyl)-, (αR,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 852236-56-7 CAPLUS
CN 2-Morpholinemethanol, α-[(2-ethoxyphenyl)methyl]-α-(2-methylpropyl)-, (αR,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.

RN 852236-65-8 CAPLUS
CN 2-Morpholinemethanol, α-[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]-α-(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-66-9 CAPLUS
CN 2-Morpholinemethanol, α-[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]-α-(2-methylpropyl)- (CA INDEX NAME)




RN 854139-85-8 CAPLUS
CN 2-Morpholinemethanol, α-[(2-chloro-6-fluorophenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 854139-86-9 CAPLUS
CN 2-Morpholinemethanol, α-[(2,5-dimethoxyphenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)-rel- (9CI) (CA INDEX NAME)




RN 852236-58-9 CAPLUS
CN 2-Morpholinemethanol, α-[(2-methylpropyl)-α-[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-60-3 CAPLUS
CN 2-Morpholinemethanol, α-[(1,1'-biphenyl)-2-ylmethyl]-α-(2-methylpropyl)- (CA INDEX NAME)




RN 852236-63-6 CAPLUS
CN 2-Morpholinemethanol, α-[(1,1'-biphenyl)-2-ylmethyl]-α-(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


Relative stereochemistry.



● HCl

RN 854139-87-0 CAPLUS
CN 2-Morpholinemethanol, α-[(2,4-difluorophenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 854139-88-1 CAPLUS
CN 2-Morpholinemethanol, α-[(2,6-dichlorophenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 854139-89-2 CAPLUS

CN 2-Morpholinemethanol, α -[(2,5-dichlorophenyl)methyl]- α -phenyl-, hydrochloride, ($\alpha R, 2S$)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 854139-90-5 CAPLUS

CN 2-Morpholinemethanol, α -[(2,5-difluorophenyl)methyl]- α -phenyl-, hydrochloride, ($\alpha R, 2S$)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 854139-91-6 CAPLUS

CN 2-Morpholinemethanol, α -[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, ($\alpha R, 2S$)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Relative stereochemistry.




● HCl

RN 857642-42-3 CAPLUS

CN 2-Morpholinemethanol, α -(3-fluorophenyl)- α -[(2-methoxyphenyl)methyl]-, hydrochloride, ($\alpha R, 2S$)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 857642-43-4 CAPLUS

CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethoxy)phenyl)methyl]-, hydrochloride, ($\alpha R, 2S$)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 857642-38-7 CAPLUS

CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -phenyl-, hydrochloride, ($\alpha R, 2S$)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 857642-40-1 CAPLUS


CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -phenyl-, hydrochloride, ($\alpha R, 2S$)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 857642-41-2 CAPLUS


CN 2-Morpholinemethanol, α -[[2-(1-methylethoxy)phenyl)methyl]- α -phenyl-, hydrochloride, ($\alpha R, 2S$)-rel- (9CI) (CA INDEX NAME)

● HCl

RN 857642-44-5 CAPLUS

CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -phenyl-, hydrochloride, ($\alpha R, 2S$)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 857642-45-6 CAPLUS

CN 2-Morpholinemethanol, α -[(2-chlorophenyl)methyl]- α -phenyl-, hydrochloride, ($\alpha R, 2S$)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 857642-48-9 CAPLUS


CN 2-Morpholinemethanol, α -phenyl- α -[[2-[(trifluoromethyl)thio]phenyl)methyl]-, ($\alpha R, 2S$)-rel-, acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 857642-47-8

CMF C19 H20 F3 N O2 S

Relative stereochemistry.



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 857642-51-4 CAPLUS

CN 2-Morpholinemethanol, α-[(2-chlorophenyl)methyl]-α-(3-fluorophenyl)-, hydrochloride, (αR,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl


RN 857642-52-5 CAPLUS

CN 2-Morpholinemethanol, α-[(2-methylphenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L25 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


Relative stereochemistry.



RN 857642-59-2 CAPLUS

CN 2-Morpholinemethanol, α-[(2'-chloro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, hydrochloride, (αR,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 857642-60-5 CAPLUS


CN 2-Morpholinemethanol, α-[(5-fluoro-2-hydroxyphenyl)methyl]-α-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 857642-61-6 CAPLUS

CN 2-Morpholinemethanol, α-[(5-fluoro-2-hydroxyphenyl)methyl]-α-phenyl- (CA INDEX NAME)




● HCl

RN 857642-54-7 CAPLUS

CN 2-Morpholinemethanol, α-phenyl-α-(phenylmethyl)-, hydrochloride, (αR,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 857642-56-9 CAPLUS

CN 2-Morpholinemethanol, α-[(2-fluorophenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 857642-57-0 CAPLUS


CN 2-Morpholinemethanol, α-[(2-bromophenyl)methyl]-α-phenyl-, (αR,2S)-rel- (CA INDEX NAME)

L25 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857642-62-7 CAPLUS

CN 2-Morpholinemethanol, α-[(4'-methyl[1,1'-biphenyl]-2-yl)methyl]-α-phenyl- (CA INDEX NAME)




RN 857642-63-8 CAPLUS

CN 2-Morpholinemethanol, α-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl- (CA INDEX NAME)




RN 857642-64-9 CAPLUS


CN 2-Morpholinemethanol, α-[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-α-phenyl- (CA INDEX NAME)




RN 857642-65-0 CAPLUS
CN 2-Morpholinemethanol, α -[(3'-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl- (CA INDEX NAME)




RN 857642-66-1 CAPLUS
CN 2-Morpholinemethanol, α -[(3'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl- (CA INDEX NAME)




RN 857642-67-2 CAPLUS
CN 2-Morpholinemethanol, α -[(3'-methoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl- (CA INDEX NAME)





RN 857642-71-8 CAPLUS
CN 2-Morpholinemethanol, α -[(2',4'-dimethoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl- (CA INDEX NAME)




RN 857642-72-9 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -[[2-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 857642-73-0 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -[[2-(3-thienyl)phenyl]methyl]- (CA INDEX NAME)




RN 857642-68-3 CAPLUS
CN 2-Morpholinemethanol, α -[(3'-methyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl- (CA INDEX NAME)



RN 857642-69-4 CAPLUS
CN 2-Morpholinemethanol, α -[(3',5'-dichloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl- (CA INDEX NAME)



RN 857642-70-7 CAPLUS
CN 2-Morpholinemethanol, α -[(2',4'-dimethyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl- (CA INDEX NAME)




RN 857642-74-1 CAPLUS
CN 2-Morpholinemethanol, α -[(3',4'-dichloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl- (CA INDEX NAME)

L25 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:523264 CAPLUS
 DOCUMENT NUMBER: 143:59831
 TITLE: A preparation of aminopiperidine derivatives, useful for the treatment of cognitive failure
 INVENTOR(S): Hatfield, Alan Kramer; Bymaster, Franklin Porter; McKinzie, David Lee; Tucker, Tina Marie; Keaffaber, Kirk Matthew; Sumner, Calvin Russell; Trzepacz, Paula Terese; Allen, Albert John; Kelsey, Douglas Kenneth; Michelson, David; Gehlert, Donald Richard; Yang, Charles Renkin
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 300 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053663	A2	20050616	WO 2004-US37195	20041124
WO 2005053663	A3	20050811		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:		US 2003-524450P	P	20031124
		US 2003-524781P	P	20031125

OTHER SOURCE(S): MARPAT 143:59831
 GI



AB The invention relates to a preparation of aminopiperidine derivs. of formula I
 [wherein: x is 1-3; R1 is (un)substituted phenyl; R2 and R5 are independently H or alkyl; R3 is (cyclo)alkyl, alkenyl, or cycloalkylalkyl,


L25 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 664360-74-1 CAPLUS
 CN 2-Morpholinemethanol, α -[[2-(1-methylethoxy)phenyl]methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-75-2 CAPLUS
 CN 2-Morpholinemethanol, α -(3-fluorophenyl)- α -[(2-methoxyphenyl)methyl]-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


L25 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 etc.; R4 is H, halogen, or OH, etc.; R6 is H, halogen, CN, or alkyl, etc.], useful for the treatment of cognitive failure. Selective norepinephrine reuptake inhibitors were used to treat cognitive failure. For instance, fumarate salt of aminopiperidine deriv. II was prepd. via imination of 2-fluorobenzaldehyde by tert-Bu 4-[(2-methylpropyl)amino]piperidine-1-carboxylate, redn. of the obtained imine, and subsequent fumaric acid salt formation. The preferred invention compds. exhibit Ki values less than 500 nM at the norepinephrine transporter.

IT 664360-72-9P 664360-73-OP 664360-74-1P
 664360-75-2P 664360-76-3P 664360-77-4P
 664360-78-5P 664360-79-6P 664360-81-0P
 664360-82-1P 664360-83-2P 664360-84-3P
 664360-85-4P 664360-86-5P 664360-87-6P
 664360-88-7P 664360-89-8P 664360-90-9P
 664360-91-0P 664360-92-1P 664360-93-2P 664360-94-3P
 664360-95-4P 664360-96-5P 664360-97-6P
 664360-98-7P 664360-99-8P 664360-100-9P
 664360-101-0P 664360-102-1P 664360-103-2P
 664360-104-3P

RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aminopiperidine derivs. useful for the treatment of cognitive failure)

RN 664360-72-9 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 664360-73-0 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 664360-76-3 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-77-4 CAPLUS
 CN 2-Morpholinemethanol, α -[(1,1'-biphenyl)-2-ylmethyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-78-5 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-chlorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-79-6 CAPLUS
 CN 2-Morpholinemethanol, α-[(5-fluoro-2-methoxyphenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-81-0 CAPLUS
 CN 2-Morpholinemethanol, α-phenyl-α-[[2-[(trifluoromethyl)thio]phenyl]methyl]-, (αR,2S)-, acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 664360-80-9
 CMP C19 H20 F3 N O2 S

Absolute stereochemistry.




CM 2

CRN 64-19-7
 CMP C2 H4 O2




RN 664360-82-1 CAPLUS
 CN 2-Morpholinemethanol, α-phenyl-α-[[2-(trifluoromethyl)phenyl]methyl]-, (αR,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664360-83-2 CAPLUS
 CN 2-Morpholinemethanol, α-[(2-chlorophenyl)methyl]-α-(3-fluorophenyl)-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-84-3 CAPLUS
 CN 2-Morpholinemethanol, α-[(2-methylphenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-85-4 CAPLUS
 CN 2-Morpholinemethanol, α-phenyl-α-(phenylmethyl)-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-86-5 CAPLUS
 CN 2-Morpholinemethanol, α-[(2-fluorophenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 664360-87-6 CAPLUS
 CN 2-Morpholinemethanol, α-[(2-bromophenyl)methyl]-α-phenyl-, (αR,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664360-88-7 CAPLUS
 CN 2-Morpholinemethanol, α-[(2'-chloro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-89-8 CAPLUS
 CN 2-Morpholinemethanol, α-[(5-fluoro-2-hydroxyphenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 854139-85-8 CAPLUS
 CN 2-Morpholinemethanol, α-[(2-chloro-6-fluorophenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 854139-86-9 CAPLUS
 CN 2-Morpholinemethanol, α-[(2,5-dimethoxyphenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




● HCl

RN 854139-87-0 CAPLUS
 CN 2-Morpholinemethanol, α-[(2,4-difluorophenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl



● HCl

RN 854139-91-6 CAPLUS
 CN 2-Morpholinemethanol, α-[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, hydrochloride, (αR,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 854139-92-7 CAPLUS
 CN 2-Morpholinemethanol, α-[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 854139-93-8 CAPLUS

RN 854139-88-1 CAPLUS
 CN 2-Morpholinemethanol, α-[(2,6-dichlorophenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 854139-89-2 CAPLUS
 CN 2-Morpholinemethanol, α-[(2,5-dichlorophenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl


RN 854139-90-5 CAPLUS
 CN 2-Morpholinemethanol, α-[(2,5-difluorophenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




CN 2-Morpholinemethanol, α-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 854139-94-9 CAPLUS
 CN 2-Morpholinemethanol, α-[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 854139-95-0 CAPLUS
 CN 2-Morpholinemethanol, α-[(3'-fluoro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.



L25 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 854139-96-1 CAPLUS
CN 2-Morpholinemethanol, α -[(3'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 854139-97-2 CAPLUS
CN 2-Morpholinemethanol, α -[(3'-methoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 854139-98-3 CAPLUS
CN 2-Morpholinemethanol, α -[(3'-methyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 854139-99-4 CAPLUS

L25 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 854140-02-6 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -[[2-(3-pyridinyl)phenyl]methyl]-, ($\alpha R, 2S$)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 854140-03-7 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -[[2-(3-thienyl)phenyl]methyl]-, ($\alpha R, 2S$)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 854140-04-8 CAPLUS
CN 2-Morpholinemethanol, α -[(3',4'-dichloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)-rel- (CA INDEX NAME)

Relative stereochemistry.




IT 664361-42-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

L25 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


CN 2-Morpholinemethanol, α -[(3',5'-dichloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 854140-00-4 CAPLUS
CN 2-Morpholinemethanol, α -[(2',4'-dimethyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 854140-01-5 CAPLUS
CN 2-Morpholinemethanol, α -[(2',4'-dimethoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)-rel- (CA INDEX NAME)

Relative stereochemistry.




L25 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(Reactant or reagent)

(prepn. of aminopiperidine derivs. useful for the treatment of cognitive failure)

RN 664361-42-6 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-hydroxyphenyl)methyl]- α -phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)

Absolute stereochemistry.





L25 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:451370 CAPLUS
DOCUMENT NUMBER: 142:482071
TITLE: Preparation of morpholine derivatives as norepinephrine reuptake inhibitors
INVENTOR(S): Campbell, Gordon Iain; Cases-Thomas, Manuel Javier; Man, Teresa; Masters, John Joseph; Rudyk, Helene Catherine Eugenie; Walter, Magnus Wilhelm
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005047272	A1	20050526	WO 2004-US32771	20041028
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004289616	A1	20050526	AU 2004-289616	20041028
CA 2544649	A1	20050526	CA 2004-2544649	20041028
EP 1682523	A1	20060726	EP 2004-794209	20041028
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
HR				
CN 1878762	A	20061213	CN 2004-80033115	20041028
BR 2004015273	A	20061219	BR 2004-15273	20041028
JP 2007510720	T	20070426	JP 2006-539492	20041028
US 2007083046	A1	20070412	US 2006-577841	20060429
MX 2006PA05226	A	20060720	MX 2006-PA5226	20060509
KR 783855	B1	20071210	KR 2006-708999	20060509
NO 2006002700	A	20060808	NO 2006-2700	20060612
PRIORITY APPLN. INFO.:			GB 2003-26148	A 20031110
			US 2004-535459P	P 20040109
			WO 2004-US32771	W 20041028


OTHER SOURCE(S): CASREACT 142:482071; MARPAT 142:482071
GI

L25 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




AB Title compds. I [X = OH, alkoxy, NH₂, etc.; R independently = H, alkyl, with provisions; R1 = (un)substituted-alkyl, -alkoxy, CN, etc.; R2 = H, alkyl; R3 = H, alkyl; Ar = (un)substituted-Ph, -5- to 6-membered heteroaryl] and their pharmaceutically acceptable salts, are prepared and disclosed as norepinephrine reuptake inhibitors. Thus, e.g., II was prepared by conversion of 4-benzyl-morpholine-2-carbonitrile into the resp. carboxylic Et ester followed by amidation with N,N-dimethylhydroxylamine and subsequent Grignard reactions with Me magnesium bromide and 2-phenylbenzyl magnesium bromide followed by debenzilation and conversion into the HCl salt. The activity of I was evaluated in a CYP2D6 inhibition assay and preferred compds. of the invention exhibited an IC₅₀ higher than 6 μ M. I as norepinephrine reuptake inhibitors should prove useful in the treatment of disorders that are associated with norepinephrine dysfunction. Pharmaceutical compds. comprising I are disclosed.
IT 852236-37-4P 852236-38-5P 852236-42-1P
852236-43-2P
RI: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of morpholine derivs. as norepinephrine reuptake inhibitors)
RN 852236-37-4 CAPLUS
CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -(1-methylethyl)-, (α R,2R)-rel- (CA INDEX NAME)

L25 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Relative stereochemistry.




RN 852236-38-5 CAPLUS
CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -(1-methylethyl)-, (α R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 852236-42-1 CAPLUS
CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -(1-methylethyl)-, (α R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 852236-43-2 CAPLUS
CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -(1-methylethyl)-, (α R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.




L25 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


IT 852236-60-3P 852237-02-6P
RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of morpholine derivs. as norepinephrine reuptake inhibitors)
RN 852236-60-3 CAPLUS
CN 2-Morpholinemethanol, α -[(1,1'-biphenyl)-2-ylmethyl]- α -(2-methylpropyl)- (CA INDEX NAME)



RN 852237-02-6 CAPLUS
CN 2-Morpholinemethanol, α -[(1,1'-biphenyl)-2-ylmethyl]- α -(4,4,4-trifluorobutyl)- (CA INDEX NAME)




IT 852236-27-2P 852236-29-4P 852236-31-8P
852236-33-0P 852236-35-2P 852236-39-6P
852236-40-9P 852236-44-3P 852236-45-4P
852236-47-6P 852236-49-8P 852236-51-2P
852236-53-4P 852236-55-6P 852236-56-7P
852236-58-9P 852236-63-6P 852236-65-8P
852236-93-2P 852236-95-4P 852236-97-6P
852236-99-8P 852237-01-5P 852237-14-0P
852237-21-9P 852237-23-1P 852237-27-5P
852237-29-7P
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of morpholine derivs. as norepinephrine reuptake inhibitors)
RN 852236-27-2 CAPLUS
CN 2-Morpholinemethanol, α -[(1,1'-biphenyl)-2-ylmethyl]- α -methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-29-4 CAPLUS
 CN 2-Morpholinemethanol, α -ethyl- α -[(5-fluoro-2-methoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-31-8 CAPLUS
 CN 2-Morpholinemethanol, α -ethyl- α -[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-33-0 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -ethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-35-2 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(1-methylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 852236-39-6 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -(1-methylethyl)-, hydrochloride, (α R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 852236-40-9 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -(1-methylethyl)-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 852236-44-3 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -(1-methylethyl)-, hydrochloride, (α R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 852236-45-4 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -(1-methylethyl)-, hydrochloride, (α R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 852236-47-6 CAPLUS
 CN 2-Morpholinemethanol, α -(1-methylethyl)- α -[[2-




● HCl

RN 852236-49-8 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -(1-methylethyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-51-2 CAPLUS
 CN 2-Morpholinemethanol, α -[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -(1-methylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-53-4 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 852236-55-6 CAPLUS
CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -(2-methylpropyl)-, (α R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 852236-56-7 CAPLUS
CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -(2-methylpropyl)-, (α R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 852236-58-9 CAPLUS
CN 2-Morpholinemethanol, α -(2-methylpropyl)- α -[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-63-6 CAPLUS
CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-65-8 CAPLUS
CN 2-Morpholinemethanol, α -[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-93-2 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(3,3,3-trifluoropropyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-95-4 CAPLUS
CN 2-Morpholinemethanol, α -[[2-(trifluoromethoxy)phenyl]methyl]- α -(3,3,3-trifluoropropyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-97-6 CAPLUS
CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -(3,3,3-trifluoropropyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852236-99-8 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -(4,4,4-trifluorobutyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852237-01-5 CAPLUS
CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -(4,4,4-trifluorobutyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852237-14-0 CAPLUS
CN 2-Morpholinemethanol, α , α -bis[(2-methoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852237-21-9 CAPLUS
CN 2-Morpholinemethanol, α -butyl- α -[(2-methoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852237-23-1 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -butyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852237-27-5 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-chloro-6-fluorophenyl)methyl]- α -(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852237-29-7 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-chlorophenyl)methyl]- α -(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 852236-66-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of morpholine derivs. as norepinephrine reuptake inhibitors)
 RN 852236-66-9 CAPLUS
 CN 2-Morpholinemethanol, α -[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -(2-methylpropyl)- (CA INDEX NAME)





REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L25 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:216719 CAPLUS
 DOCUMENT NUMBER: 142:291416
 TITLE: Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
 Kelsey, Douglas Kenneth
 INVENTOR(S):
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 299 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005021095	A2	20050310	WO 2004-US25591	20040825
WO 2005021095	A3	20050609		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TH, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2532349	A1	20050310	CA 2004-2532349	20040825
EP 1660185	A2	20060531	EP 2004-780429	20040825
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
US 2007032554	A1	20070208	US 2006-568269	20060214
PRIORITY APPLN. INFO.:			US 2003-498018P	P 20030827
			WO 2004-US25591	W 20040825

OTHER SOURCE(S): MARPAT 142:291416
 GI




AB Provided are methods and medicaments for treating stuttering or another communication disorder, comprising administering to a patient in need of such treatment an effective amount of a selective norepinephrine reuptake inhibitor. The invention discloses the use of atomoxetine, racemic reboxetine, (S,S)-reboxetine, and compds. of formula I [wherein X = alkylthio and Y = alkyl; as described in U.S. patent Number 5,281,624],

as well as their pharmaceutically acceptable salts, as the norepinephrine reuptake inhibitors described for treatment purposes. The invention further discloses the preparation of addnl. heterocyclic derivs. (as well as their pharmaceutically acceptable salts) that possess ability to serve as norepinephrine reuptake inhibitors. For instance, morpholine derivative I●HCl was prepared via alkylation of (4-benzyl-morpholin-2-yl)(phenyl)methanone with 2-chloro-6-fluorobenzylmagnesium chloride and subsequent N-debenzylation. The preferred invention compds. exhibited KI values of less than 500 nM at the norepinephrine transporter (scintillation proximity assay).

IT 664360-72-9P 664360-73-OP 664360-74-1P
 664360-75-2P 664360-76-3P 664360-77-4P
 664360-78-5P 664360-79-6P 664360-81-OP
 664360-82-1P 664360-83-2P 664360-84-3P
 664360-85-4P 664360-86-5P 664360-87-6P
 664360-88-7P 664360-89-8P 664360-90-1P
 664360-91-2P 664360-92-3P 664360-93-4P
 664360-94-5P 664360-95-6P 664360-96-7P
 664360-97-8P 664360-98-9P 664360-99-OP
 664361-00-6P 664361-01-7P 664361-02-8P
 664361-03-9P 664361-04-OP 664361-05-1P
 664361-06-2P 664361-07-3P 664361-08-4P
 664361-09-5P 664361-42-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

L25 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (prepn. of heterocyclic compds. useful as norepinephrine reuptake
 inhibitors)
 RN 664360-72-9 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -phenyl-,
 hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-73-0 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -phenyl-,
 hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-74-1 CAPLUS
 CN 2-Morpholinemethanol, α -[[2-(1-methylethoxy)phenyl]methyl]- α -
 phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L25 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 664360-75-2 CAPLUS
 CN 2-Morpholinemethanol, α -(3-fluorophenyl)- α -[(2-
 methoxyphenyl)methyl]-, hydrochloride, (α R,2S)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




● HCl

RN 664360-76-3 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-
 (trifluoromethoxy)phenyl]methyl]-, hydrochloride, (α R,2S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.


L25 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 664360-77-4 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -phenyl-,
 hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-78-5 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-chlorophenyl)methyl]- α -phenyl-,
 hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-79-6 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -
 phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

L25 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 Absolute stereochemistry.




● HCl

RN 664360-81-0 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-
 [(trifluoromethylthio)phenyl]methyl]-, (α R,2S)-, acetate (salt)
 (9CI) (CA INDEX NAME)

CM 1

CRN 664360-80-9
 CMF C19 H20 F3 N O2 S

Absolute stereochemistry.




CM 2

CRN 64-19-7
 CMF C2 H4 O2




RN 664360-82-1 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-
 (trifluoromethylthio)phenyl]methyl]-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664360-83-2 CAPLUS
CN 2-Morpholinemethanol, α -[(2-chlorophenyl)methyl]- α -(3-fluorophenyl)-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 664360-84-3 CAPLUS
CN 2-Morpholinemethanol, α -[(2-methylphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 664360-85-4 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -(phenylmethyl)-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)



● HCl

RN 664360-86-5 CAPLUS
CN 2-Morpholinemethanol, α -[(2-fluorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 664360-87-6 CAPLUS
CN 2-Morpholinemethanol, α -[(2-bromophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 664360-88-7 CAPLUS
CN 2-Morpholinemethanol, α -[(2'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-89-8 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-hydroxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-90-1 CAPLUS
CN 2-Morpholinemethanol, α -[(2-chloro-6-fluorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-91-2 CAPLUS
CN 2-Morpholinemethanol, α -[(2,5-dimethoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-92-3 CAPLUS
CN 2-Morpholinemethanol, α -[(2,4-difluorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-93-4 CAPLUS
CN 2-Morpholinemethanol, α -[(2,6-dichlorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L25 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 664360-94-5 CAPLUS
CN 2-Morpholinemethanol, α-[(2,5-dichlorophenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-95-6 CAPLUS
CN 2-Morpholinemethanol, α-[(2,5-difluorophenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 664360-96-7 CAPLUS

L25 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 664360-99-0 CAPLUS
CN 2-Morpholinemethanol, α-[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664361-00-6 CAPLUS
CN 2-Morpholinemethanol, α-[(3'-fluoro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 664361-01-7 CAPLUS
CN 2-Morpholinemethanol, α-[(3'-chloro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)- (CA INDEX NAME)

L25 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2-Morpholinemethanol, α-[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-97-8 CAPLUS
CN 2-Morpholinemethanol, α-[(4'-methyl[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664360-98-9 CAPLUS
CN 2-Morpholinemethanol, α-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)- (CA INDEX NAME)

Absolute stereochemistry.


L25 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 664361-02-8 CAPLUS
CN 2-Morpholinemethanol, α-[(3'-methoxy[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-03-9 CAPLUS
CN 2-Morpholinemethanol, α-[(3'-methyl[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-04-0 CAPLUS
CN 2-Morpholinemethanol, α-[(3',5'-dichloro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-05-1 CAPLUS
CN 2-Morpholinemethanol, α-[(2',4'-dimethyl[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-06-2 CAPLUS
CN 2-Morpholinemethanol, α-[(2',4'-dimethoxy[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 664361-07-3 CAPLUS
CN 2-Morpholinemethanol, α-phenyl-α-[[2-(3-pyridinyl)phenyl]methyl]-, (αR,2S)- (CA INDEX NAME)




Absolute stereochemistry.




RN 664361-08-4 CAPLUS
CN 2-Morpholinemethanol, α-phenyl-α-[[2-(3-thienyl)phenyl]methyl]-, (αR,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664361-09-5 CAPLUS
CN 2-Morpholinemethanol, α-[(3',4'-dichloro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-42-6 CAPLUS
CN 2-Morpholinemethanol, α-[(5-fluoro-2-hydroxyphenyl)methyl]-α-phenyl-, (αR,2S)- (CA INDEX NAME)

Absolute stereochemistry.

ACCESSION NUMBER: 2005:216660 CAPLUS
DOCUMENT NUMBER: 142:291415
TITLE: Treatment of pervasive development disorders
employing
norepinephrine reuptake inhibitors
INVENTOR(S): Allen, Albert John; Kelsey, Douglas Kenneth
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 300 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020976	A2	20050310	WO 2004-US25593	20040825
WO 2005020976	A3	20050616		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2536161	A1	20050310	CA 2004-2536161	20040825
EP 1660065	A2	20060531	EP 2004-780431	20040825
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 2006241188	A1	20061026	US 2006-568466	20060214
PRIORITY APPLN. INFO.:				P 20030827
				WO 2004-US25593 W 20040825

OTHER SOURCE(S): CASREACT 142:291415; MARPAT 142:291415
GI



AB Provided are methods and medicaments for treating a pervasive development disorder, comprising administering to a patient in need of such treatment

L25 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 an effective amt. of a selective norepinephrine reuptake inhibitor. The invention discloses the use of atomoxetine, racemic reboxetine, (S,S)-reboxetine, and compds. of formula I [wherein X = alkylthio and Y = alkyl; as described in U.S. patent No. 5,281,624], as well as their pharmaceutically acceptable salts, as the norepinephrine reuptake inhibitors described for treatment purposes. The invention further discloses the prepn. of addnl. heterocyclic derivs. (as well as their pharmaceutically acceptable salts) that possess ability to serve as norepinephrine reuptake inhibitors. For instance, morpholine deriv. II•HCl (R = H) was prepd. via alkylation of (4-benzyl-morpholin-2-yl) (phenyl)methanone by 2-chloro-6-fluorobenzylmagnesium chloride and subsequent N-debenzylation of the obtained alc. I (R = Bn). The preferred


invention compds. exhibited Ki values of less than 500 nM at the norepinephrine transporter (scintillation proximity assay).
 IT 664360-72-9P 664360-73-0P 664360-74-1P
 664360-75-2P 664360-76-3P 664360-77-4P
 664360-78-5P 664360-79-6P 664360-81-0P
 664360-82-1P 664360-83-2P 664360-84-3P
 664360-85-4P 664360-86-5P 664360-87-6P
 664360-88-7P 664360-89-8P 664360-90-1P
 664360-91-2P 664360-92-3P 664360-93-4P
 664360-94-5P 664360-95-6P 664360-96-7P
 664360-97-8P 664360-98-9P 664360-99-0P
 664361-00-6P 664361-01-7P 664361-02-8P
 664361-03-9P 664361-04-0P 664361-05-1P
 664361-06-2P 664361-07-3P 664361-08-4P
 664361-09-5P 664361-42-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. useful as norepinephrine reuptake inhibitors)

RN 664360-72-9 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-73-0 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 664360-76-3 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-77-4 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-78-5 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-chlorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L25 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 664360-74-1 CAPLUS
 CN 2-Morpholinemethanol, α -[[2-(1-methylethoxy)phenyl]methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 664360-75-2 CAPLUS
 CN 2-Morpholinemethanol, α -(3-fluorophenyl)- α -[(2-methoxyphenyl)methyl]-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


L25 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 664360-79-6 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-81-0 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-[(trifluoromethyl)thio]phenyl]methyl]-, (α R,2S)-, acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 664360-80-9
 CMP C19 H20 F3 N O2 S

Absolute stereochemistry.



L25 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


CM 2

CRN 64-19-7
CMF C2 H4 O2




RN 664360-82-1 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethyl)phenyl]methyl]-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664360-83-2 CAPLUS
CN 2-Morpholinemethanol, α -[(2-chlorophenyl)methyl]- α -(3-fluorophenyl)-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-84-3 CAPLUS
CN 2-Morpholinemethanol, α -[(2-methylphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L25 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 664360-88-7 CAPLUS
CN 2-Morpholinemethanol, α -[(2'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-89-8 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-hydroxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-90-1 CAPLUS
CN 2-Morpholinemethanol, α -[(2-chloro-6-fluorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


L25 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 664360-85-4 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -(phenylmethyl)-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-86-5 CAPLUS
CN 2-Morpholinemethanol, α -[(2-fluorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-87-6 CAPLUS
CN 2-Morpholinemethanol, α -[(2-bromophenyl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

L25 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


Absolute stereochemistry.



● HCl

RN 664360-91-2 CAPLUS
CN 2-Morpholinemethanol, α -[(2,5-dimethoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-92-3 CAPLUS
CN 2-Morpholinemethanol, α -[(2,4-difluorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-93-4 CAPLUS
 CN 2-Morpholinemethanol, α -[(2,6-dichlorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-94-5 CAPLUS
 CN 2-Morpholinemethanol, α -[(2,5-dichlorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-95-6 CAPLUS
 CN 2-Morpholinemethanol, α -[(2,5-difluorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-96-7 CAPLUS
 CN 2-Morpholinemethanol, α -[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-97-8 CAPLUS
 CN 2-Morpholinemethanol, α -[(4'-methyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 664360-98-9 CAPLUS


L25 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN 2-Morpholinemethanol, α -[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664360-99-0 CAPLUS
 CN 2-Morpholinemethanol, α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-00-6 CAPLUS
 CN 2-Morpholinemethanol, α -[(3'-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-01-7 CAPLUS
 CN 2-Morpholinemethanol, α -[(3'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-02-8 CAPLUS
 CN 2-Morpholinemethanol, α -[(3'-methoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664361-03-9 CAPLUS
 CN 2-Morpholinemethanol, α -[(3'-methyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 664361-04-0 CAPLUS


L25 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2-Morpholinemethanol, α -[(3',5'-dichloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-05-1 CAPLUS
CN 2-Morpholinemethanol, α -[(2',4'-dimethyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-06-2 CAPLUS
CN 2-Morpholinemethanol, α -[(2',4'-dimethoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)

Absolute stereochemistry.



L25 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)


Absolute stereochemistry.



L25 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 664361-07-3 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -[[2-(3-pyridinyl)phenyl]methyl]-, ($\alpha R, 2S$)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-08-4 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -[[2-(3-thienyl)phenyl]methyl]-, ($\alpha R, 2S$)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664361-09-5 CAPLUS
CN 2-Morpholinemethanol, α -[(3',4'-dichloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, ($\alpha R, 2S$)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-42-6 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-hydroxyphenyl)methyl]- α -


L25 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:216659 CAPLUS
DOCUMENT NUMBER: 142:291414
TITLE: Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
INVENTOR(S): Sumner, Calvin Russell
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 304 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020975	A2	20050310	WO 2004-US25592	20040825
WO 2005020975	A3	20050602		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2530014	A1	20050310	CA 2004-2530014	20040825
EP 1660064	A2	20060531	EP 2004-780430	20040825
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
US 2007105960	A1	20070510	US 2006-568244	20060214
PRIORITY APPLN. INFO.:			US 2003-498019P	P 20030827
			WO 2004-US25592	W 20040825

OTHER SOURCE(S): MARPAT 142:291414
GI



I




II

AB Provided are methods and medicaments for treating a learning disability or
a motor skills disorder, comprising administering to a patient in need of
such treatment an effective amount of a selective norepinephrine reuptake
inhibitor. The invention discloses the use of atomoxetine, racemic
reboxetine, (S,S)-reboxetine, and compds. of formula I [wherein X =
alkylthio and Y = alkyl; as described in U.S. patent Number 5,281,624],

as well as their pharmaceutically acceptable salts, as the norepinephrine
reuptake inhibitors described for treatment purposes. The invention
further discloses the preparation of addnl. heterocyclic derivs. (as
well as their pharmaceutically acceptable salts) that possess ability to serve as
norepinephrine reuptake inhibitors. For instance, morpholine derivative
II•HCl was prepared via alkylation of (4-benzyl-morpholin-2-
yl)(phenyl)methanone with 2-chloro-6-fluorobenzylmagnesium chloride and
subsequent N-debenzylation. The preferred invention compds. exhibited KI
values of less than 500 nM at the norepinephrine transporter
(scintillation proximity assay).


IT 664360-72-9P 664360-73-0P 664360-74-1P
664360-75-2P 664360-76-3P 664360-77-4P
664360-78-5P 664360-79-6P 664360-81-0P
664360-82-1P 664360-83-2P 664360-84-3P
664360-85-4P 664360-86-5P 664360-87-6P
664360-88-7P 664360-89-8P 664360-90-1P
664360-91-2P 664360-92-3P 664360-93-4P
664360-94-5P 664360-95-6P 664360-96-7P
664360-97-8P 664360-98-9P 664360-99-0P
664361-00-6P 664361-01-7P 664361-02-8P
664361-03-9P 664361-04-0P 664361-05-1P
664361-06-2P 664361-07-3P 664361-08-4P
664361-09-5P 664361-42-6P



● HCl

RN 664360-75-2 CAPLUS
CN 2-Morpholinemethanol, α -(3-fluorophenyl)- α -[(2-methoxyphenyl)methyl]-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 664360-76-3 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -[(2-(trifluoromethoxy)phenyl)methyl]-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclic compds. useful as norepinephrine reuptake inhibitors)

RN 664360-72-9 CAPLUS
CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-73-0 CAPLUS
CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-74-1 CAPLUS
CN 2-Morpholinemethanol, α -[(2-(1-methylethoxy)phenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-77-4 CAPLUS
CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-78-5 CAPLUS
CN 2-Morpholinemethanol, α -[(2-chlorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-79-6 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

L25 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Absolute stereochemistry.



● HCl


RN 664360-81-0 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -[[2-
[(trifluoromethyl)thio]phenylmethyl]-, (α R,2S)-, acetate (salt)
(9CI) (CA INDEX NAME)

CM 1

CRN 664360-80-9

CMF C19 H20 F3 N O2 S

Absolute stereochemistry.



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 664360-82-1 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -[[2-
(trifluoromethyl)phenylmethyl]-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.


L25 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Absolute stereochemistry.



● HCl

RN 664360-86-5 CAPLUS
CN 2-Morpholinemethanol, α -[(2-fluorophenyl)methyl]- α -phenyl-,
hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-87-6 CAPLUS
CN 2-Morpholinemethanol, α -[(2-bromophenyl)methyl]- α -phenyl-,
(α R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 664360-88-7 CAPLUS
CN 2-Morpholinemethanol, α -[(2'-chloro[1,1'-biphenyl]-2-yl)methyl]-
 α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L25 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 664360-83-2 CAPLUS
CN 2-Morpholinemethanol, α -[(2-chlorophenyl)methyl]- α -(3-
fluorophenyl)-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-84-3 CAPLUS
CN 2-Morpholinemethanol, α -[(2-methylphenyl)methyl]- α -phenyl-,
hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-85-4 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -(phenylmethyl)-,
hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


L25 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 664360-89-8 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-hydroxyphenyl)methyl]- α -
phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-90-1 CAPLUS
CN 2-Morpholinemethanol, α -[(2-chloro-6-fluorophenyl)methyl]- α -
phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-91-2 CAPLUS
 CN 2-Morpholinemethanol, α -[(2,5-dimethoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-92-3 CAPLUS
 CN 2-Morpholinemethanol, α -[(2,4-difluorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-93-4 CAPLUS
 CN 2-Morpholinemethanol, α -[(2,6-dichlorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN 2-Morpholinemethanol, α -[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 664360-97-8 CAPLUS
 CN 2-Morpholinemethanol, α -[(4'-methyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664360-98-9 CAPLUS
 CN 2-Morpholinemethanol, α -[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-94-5 CAPLUS
 CN 2-Morpholinemethanol, α -[(2,5-dichlorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 664360-95-6 CAPLUS
 CN 2-Morpholinemethanol, α -[(2,5-difluorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-96-7 CAPLUS




RN 664360-99-0 CAPLUS
 CN 2-Morpholinemethanol, α -[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-00-6 CAPLUS
 CN 2-Morpholinemethanol, α -[(3'-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-01-7 CAPLUS
 CN 2-Morpholinemethanol, α -[(3'-chloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-02-8 CAPLUS
 CN 2-Morpholinemethanol, α -[(3'-methoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664361-03-9 CAPLUS
 CN 2-Morpholinemethanol, α -[(3'-methyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 664361-04-0 CAPLUS
 CN 2-Morpholinemethanol, α -[(3',5'-dichloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 664361-08-4 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-(3-thienyl)phenyl]methyl]-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-09-5 CAPLUS
 CN 2-Morpholinemethanol, α -[(3',4'-dichloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-42-6 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-hydroxyphenyl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-05-1 CAPLUS
 CN 2-Morpholinemethanol, α -[(2',4'-dimethyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-06-2 CAPLUS
 CN 2-Morpholinemethanol, α -[(2',4'-dimethoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664361-07-3 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-(3-pyridinyl)phenyl]methyl]-, (α R,2S)- (CA INDEX NAME)



L25 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1036891 CAPLUS
DOCUMENT NUMBER: 142:16841
TITLE: Treatment of emotional dysregulation
INVENTOR(S): Allen, Albert John; Cloutier, Kathleen Ann;
Michelson,
David; Reimherr, Frederick William
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 155 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103356	A2	20041202	WO 2004-US13005	20040511
WO 2004103356	A3	20050331		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-470752P P 20030515

OTHER SOURCE(S): MARPAT 142:16841
AB Provided is a method of treating emotional dysregulation comprising administering to a patient in need of such treatment a selective norepinephrine reuptake inhibitor.


IT 664360-72-9P 664360-73-0P 664360-74-1P
664360-76-3P 664360-77-4P 664360-78-5P
664360-79-6P 664360-81-0P 664360-82-1P
664360-83-2P 664360-84-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(treatment of emotional dysregulation)

RN 664360-72-9 CAPLUS
CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L25 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 664360-73-0 CAPLUS
CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-74-1 CAPLUS
CN 2-Morpholinemethanol, α -[[2-(1-methylethoxy)phenyl]methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-76-3 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

L25 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


Absolute stereochemistry.



● HCl

RN 664360-77-4 CAPLUS
CN 2-Morpholinemethanol, α -[(1,1'-biphenyl)-2-ylmethyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-78-5 CAPLUS
CN 2-Morpholinemethanol, α -[(2-chlorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-79-6 CAPLUS
CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -

L25 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




● HCl

RN 664360-81-0 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -[[2-[(trifluoromethyl)thio]phenyl]methyl]-, (α R,2S)-, acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 664360-80-9
CMP C19 H20 F3 N O2 S

Absolute stereochemistry.



CM 2


CRN 64-19-7
CMP C2 H4 O2



RN 664360-82-1 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethyl)phenyl]methyl]-, (α R,2S)- (CA INDEX NAME)


Absolute stereochemistry.

L25 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 664360-83-2 CAPLUS
CN 2-Morpholinemethanol, α-[(2-chlorophenyl)methyl]-α-(3-fluorophenyl)-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-84-3 CAPLUS
CN 2-Morpholinemethanol, α-[(2-methylphenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

L25 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:182855 CAPLUS
DOCUMENT NUMBER: 140:217649
TITLE: Preparation of aryl and heteroaryl morpholine derivatives as norepinephrine reuptake inhibitors
INVENTOR(S): Cases-Thomas, Manuel Javier; Haughton, Helen Louise; Lamas-Peteira, Carlos; Ouwerkerk-Mahadevan, Sivi; Masters, John Joseph; Simmonds, Robin George; Rudyk, Helene Catherine Eugenie; Walter, Magnus Wilhelm
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXKD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018441	A1	20040304	WO 2003-US23270	20030818
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003268024	A1	20040311	AU 2003-268024	20030818
EP 1534694	A1	20050601	EP 2003-748975	20030818
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 2006003998	A1	20060105	US 2005-524921	20050215
PRIORITY APPLN. INFO.:			GB 2002-19687	A 20020823
			US 2002-415303P	P 20021001
			WO 2003-US23270	W 20030818

OTHER SOURCE(S): MARPAT 140:217649
GI



L25 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB Morpholine derivs. of formula I [R = independently H, alkyl; R1 = H, alkyl; Y = OH, alkoxy; Ar1, Ar2 = (substituted) Ph, (substituted) heteroaryl] are prepared. The compds. are selective inhibitors of the reuptake of norepinephrine. Thus, II.HCl was prepared from (4-benzylmorpholin-2-yl)-phenylmethanone (preparation given) and 2-(trifluoromethoxy)benzyl bromide. The compds. had Ki values less than 500 nM at the norepinephrine transporter in a scintillation proximity assay.


IT 664360-97-8P 664360-98-9P 664360-99-0P
664361-00-6P 664361-01-7P 664361-02-8P
664361-03-9P 664361-04-0P 664361-05-1P
664361-06-2P 664361-07-3P 664361-08-4P
664361-09-5P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(preparation of aryl and heteroaryl morpholine derivs. as norepinephrine reuptake inhibitors)

RN 664360-97-8 CAPLUS
CN 2-Morpholinemethanol, α-[(4'-methyl[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 664360-98-9 CAPLUS
CN 2-Morpholinemethanol, α-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)- (CA INDEX NAME)


Absolute stereochemistry.

L25 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 664360-99-0 CAPLUS
CN 2-Morpholinemethanol, α-[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664361-00-6 CAPLUS
CN 2-Morpholinemethanol, α-[(3'-fluoro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 664361-01-7 CAPLUS
CN 2-Morpholinemethanol, α-[(3'-chloro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, (αR,2S)- (CA INDEX NAME)


L25 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 664361-02-8 CAPLUS
CN 2-Morpholinemethanol, α -[(3'-methoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664361-03-9 CAPLUS
CN 2-Morpholinemethanol, α -[(3'-methyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-04-0 CAPLUS
CN 2-Morpholinemethanol, α -[(3',5'-dichloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.


L25 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 664361-08-4 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -[[2-(3-thienyl)phenyl]methyl]-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-09-5 CAPLUS
CN 2-Morpholinemethanol, α -[(3',4'-dichloro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 664360-87-6P
RL: CRT (Combinatorial reactant); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of aryl and heteroaryl morpholine derivs. as norepinephrine reuptake inhibitors)

L25 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 664361-05-1 CAPLUS
CN 2-Morpholinemethanol, α -[(2',4'-dimethyl[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 664361-06-2 CAPLUS
CN 2-Morpholinemethanol, α -[(2',4'-dimethoxy[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 664361-07-3 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -[[2-(3-pyridinyl)phenyl]methyl]-, (α R,2S)- (CA INDEX NAME)

L25 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


reuptake inhibitors)
RN 664360-87-6 CAPLUS
CN 2-Morpholinemethanol, α -[(2-bromophenyl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 664361-41-5P
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROCS (Process); USES (Uses)
(preparation of aryl and heteroaryl morpholine derivs. as norepinephrine reuptake inhibitors)
RN 664361-41-5 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethyl)phenyl]methyl]-, (α R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.




IT 664360-82-1P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl and heteroaryl morpholine derivs. as norepinephrine reuptake inhibitors)
RN 664360-82-1 CAPLUS
CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethyl)phenyl]methyl]-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 664360-79-6P 664361-42-6P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of aryl and heteroaryl morpholine derivs. as norepinephrine reuptake inhibitors)
 RN 664360-79-6 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 664361-42-6 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-hydroxyphenyl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 664360-72-9P 664360-73-OP 664360-74-1P
 664360-75-2P 664360-76-3P 664360-77-4P
 664360-78-5P 664360-81-OP 664360-83-2P
 664360-84-3P 664360-85-4P 664360-86-5P



● HCl

RN 664360-75-2 CAPLUS
 CN 2-Morpholinemethanol, α -(3-fluorophenyl)- α -[(2-methoxyphenyl)methyl]-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 664360-76-3 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethoxy)phenyl]methyl]-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

664360-88-7P 664360-89-8P 664360-90-1P
 664360-91-2P 664360-92-3P 664360-93-4P
 664360-94-5P 664360-95-6P 664360-96-7P
 664361-37-9P 664361-38-OP 664361-39-1P
 664361-40-4P

RL: PAC (Pharmacological activity); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of aryl and heteroaryl morpholine derivs. as norepinephrine reuptake inhibitors)

RN 664360-72-9 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-methoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-73-0 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-ethoxyphenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-74-1 CAPLUS
 CN 2-Morpholinemethanol, α -[[2-(1-methylethoxy)phenyl]methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-77-4 CAPLUS
 CN 2-Morpholinemethanol, α -([1,1'-biphenyl]-2-ylmethyl)- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-78-5 CAPLUS
 CN 2-Morpholinemethanol, α -[(2-chlorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 664360-81-0 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethylthio)phenyl]methyl]-, (α R,2S)-, acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 664360-80-9

CMF C19 H20 F3 N O2 S

Absolute stereochemistry.



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 664360-83-2 CAPLUS

CN 2-Morpholinemethanol, α-[(2-chlorophenyl)methyl]-α-(3-fluorophenyl)-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-84-3 CAPLUS

CN 2-Morpholinemethanol, α-[(2-methylphenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.




● HCl

RN 664360-89-8 CAPLUS

CN 2-Morpholinemethanol, α-[(5-fluoro-2-hydroxyphenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-90-1 CAPLUS

CN 2-Morpholinemethanol, α-[(2-chloro-6-fluorophenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-85-4 CAPLUS

CN 2-Morpholinemethanol, α-phenyl-α-(phenylmethyl)-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-86-5 CAPLUS

CN 2-Morpholinemethanol, α-[(2-fluorophenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-88-7 CAPLUS

CN 2-Morpholinemethanol, α-[(2'-chloro[1,1'-biphenyl]-2-yl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.




● HCl

RN 664360-91-2 CAPLUS

CN 2-Morpholinemethanol, α-[(2,5-dimethoxyphenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-92-3 CAPLUS

CN 2-Morpholinemethanol, α-[(2,4-difluorophenyl)methyl]-α-phenyl-, hydrochloride, (αR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-93-4 CAPLUS

L25 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN 2-Morpholinemethanol, α -[(2,6-dichlorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 664360-94-5 CAPLUS
 CN 2-Morpholinemethanol, α -[(2,5-dichlorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 664360-95-6 CAPLUS
 CN 2-Morpholinemethanol, α -[(2,5-difluorophenyl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L25 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl


RN 664360-96-7 CAPLUS
 CN 2-Morpholinemethanol, α -[(4-fluoro[1,1'-biphenyl]-2-yl)methyl]- α -phenyl-, hydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 664361-37-9 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 664361-38-0 CAPLUS
 CN 2-Morpholinemethanol, α -phenyl- α -[[2-(trifluoromethoxy)phenyl]methyl]-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 664361-39-1 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -phenyl- (CA INDEX NAME)




RN 664361-40-4 CAPLUS
 CN 2-Morpholinemethanol, α -[(5-fluoro-2-methoxyphenyl)methyl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L25 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1985:24560 CAPLUS
 DOCUMENT NUMBER: 102:24560
 ORIGINAL REFERENCE NO.: 102:4051a,4054a
 TITLE: Potential antidepressant agents. α -Aryloxy-benzyl derivatives of ethanolamine and morpholine
 AUTHOR(S): Melloni, Piero; Carniel, Giovanni; Della Torre, Arturo; Bonsignori, Alberto; Buonamici, Matilde; Pozzi, Ottorino; Ricciardi, Sante; Rossi, Alessandro C.
 CORPORATE SOURCE: Farmitalia C. Erba S.p.A., Milan, 20159, Italy
 SOURCE: European Journal of Medicinal Chemistry (1984), 19(3), 235-42
 CODEN: EJMCA5; ISSN: 0223-5234
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 102:24560
 GI




AB The title compds. I and II (R = Me, H, Cl, MeO, methylenedioxy; R1 = H, Me, R2 = H, MeO, Cl; R3 = H, Me, Me2CH; R4, R5 = H, Me; R6 = H, Me, Ac, MeNHCO, etc.; X = O, CH2, MeN) were prepared as antidepressants from phenoxyacetates III (R7 = Et). Thus, III (R = 2-MeO, R1 = R2 = R7 = H) was treated with carbonyldiimidazole and nitromethane sodium salt to give the nitro enolate, which was reduced by H2/PtO2 to give 2 diastereoisomers of I (R = 2-MeO, R1-R5 H). II (R = 2-EtO, R1 = R2 = R6 = H; X = O) showed outstanding activity in the antiserpine test when compared with Imipramine, Desipramine and Viloxazine.
 IT 93852-76-7
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
 USES (Uses)
 (antidepressant activity of)
 RN 93852-76-7 CAPLUS

L25 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN Morpholine, 2-[1-(2-methoxyphenoxy)-1-phenylethyl]- (CA INDEX NAME)



IT 93851-95-7P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antidepressant activity of)
RN 93851-95-7 CAPLUS
CN Morpholine, 2-[1-(2-methoxyphenoxy)-1-phenylethyl]-, hydrochloride (9CI)
(CA INDEX NAME)



● HCl

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

76.78

1213.33

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-11.20

-22.40

STN INTERNATIONAL LOGOFF AT 12:23:58 ON 14 FEB 2008